Cocoa Polyphenols and Inflammatory Markers of Cardiovascular Disease

Nasiruddin Khan 1,2,†, Olha Khymenets 2,†,*, Mireia Urpí-Sardà 2, Sara Tulipani 2,3, Mar García-Aloy 2, María Monagas 4, Ximena Mora-Cubillos 2, Rafael Llorach 2 and Cristina Andres-Lacueva 2

1 Biomarkers Research Program, Biochemistry Department, College of Science, King Saud University, P.O. Box 2455, King Abdullah road, Riyadh 11451, Saudi Arabia; E-Mail: nasiruddin2006@gmail.com
2 Biomarkers and Nutritional & Food Metabolomics Research Group, Department of Nutrition and Food Science, XaRTA, INSA, Campus Torribera; INGENIO-CONSOLIDER Program, Fun-C-Food CSD2007-063, Ministry of Science and Innovation, Faculty of Pharmacy, University of Barcelona, Av Joan XXIII, s/n, Barcelona 08028, Spain; E-Mails: murpi@ub.edu (M.U.-S.); sara.tulipani@gmail.com (S.T.); margarcia@ub.edu (M.G.-A.); ximenamora@ub.edu (X.M.-C.); rafallorach@ub.edu (R.L.); candres@ub.edu (C.A.-L.)
3 Biomedical Research Institute (IBIMA), Service of Endocrinology and Nutrition, Hospital Complex (Virgen de la Victoria), Campus de Teatinos s/n, University of Málaga, Malaga 29010, Spain
4 Institute of Food Science Research (CIAL), CSIC-UAM. C/Nicolás Cabrera 9, Campus de Cantoblanco, Madrid 28049, Spain; E-Mail: m.monagas@csic.es

† These authors contributed equally to this work.

* Author to whom correspondence should be addressed; E-Mail:okhymenets@ub.edu; Tel.: +34-93-40-35-930; Fax: +34-93-40-35-931.

Received: 29 November 2013; in revised form: 30 December 2013 / Accepted: 6 February 2014 / Published: 21 February 2014

Abstract: Epidemiological studies have demonstrated the beneficial effect of plant-derived food intake in reducing the risk of cardiovascular disease (CVD). The potential bioactivity of cocoa and its polyphenolic components in modulating cardiovascular health is now being studied worldwide and continues to grow at a rapid pace. In fact, the high polyphenol content of cocoa is of particular interest from the nutritional and pharmacological viewpoints. Cocoa polyphenols are shown to possess a range of cardiovascular-protective properties, and can play a meaningful role through modulating different inflammatory
markers involved in atherosclerosis. Accumulated evidence on related anti-inflammatory effects of cocoa polyphenols is summarized in the present review.

**Keywords:** cocoa polyphenols; bioavailability; inflammation; CVD

1. Introduction

Of an estimated 17.3 million deaths globally from all causes in 2008, cardiovascular disease (CVD) accounted for 30% [1]. The cardiovascular epidemic is rapidly advancing in the world. It has been projected that by 2030 nearly 23.6 million people will die from cardiovascular disorders [2,3]. However, the majority of these deaths caused by CVD are preventable [4,5]. Epidemiological and clinical studies have shown that lifestyle modifications such as nutrition and exercise are initial protective measures to reduce the risk of CVD [6–9]. The consumption of plant-derived food, such as whole grains, fruits, and vegetables, has been recognized as one of the principal preventive factors in the risk of all-cause and CVD mortality [10–12]. Moreover, the absolute quantity and frequency of fruit and vegetable intake have been associated with lower CVD risk and, therefore, with lower CVD mortality [13,14]. The mechanisms by which fruit and vegetables exert their protective effects are not entirely clear, but experimental and population studies [15,16] have indicated that plant polyphenols are principal mediators. Numerous scientific reports accumulated over recent decades suggest that plant polyphenols may exert their activities on the antioxidant system, signaling and transcription pathways, thus affecting principal mechanisms involved in cardiovascular events, such as systemic inflammation, lipid metabolism, hemostatic and vascular events, and immune response [17–23].

Cocoa products are among the richest sources of polyphenols in our diets. Nowadays cocoa has become a widely consumed food component, with growing demand across the world [24]. Interest in the biological activities of cocoa (*Theobroma cacao*) polyphenols has increased steadily, since the first studies on the positive link between plant food polyphenol consumption and health outcomes were reported. Cocoa has the highest flavanol content of all foods on a per-weight basis and is a significant contributor to the total dietary intake of flavonoids [25,26]. Depending upon geographical origins and plant varieties, the total polyphenol content of cocoa ranges from 40.0 mg GAE/g (GAE; gallic acid equivalent) to 84.2 mg GAE/g [27–30]. However, portions in chocolate, the most commonly consumed processed cocoa product, are significantly lower, with levels of 1.7–8.4 mg/g reported in dark chocolate and even lower levels of 0.7–5 mg/g in milk chocolate [31,32].

Several population studies have reported on the inverse association between cocoa intake (e.g., chocolate) and CVD mortality [33,34]. A number of recent meta-analyses of intervention studies have demonstrated that there is substantial evidence that cocoa consumption affects multiple cardiovascular risk factors such as blood pressure [35], insulin resistance [36], lipid profiles [37], and flow-mediated vascular dilatation (FMD) [38]. On the other hand, there are numerous *in vitro* and *in vivo* experimental data supporting the notion that polyphenols may mediate these beneficial effects of cocoa [39–41].

Nowadays, it has become more evident that inflammatory mediators play a key role in the pathology of atherosclerosis, starting from the initial phases of leukocyte recruitment, and finishing with the eventual rupture of the vulnerable atherosclerotic plaque [42–44]. Therefore, atherosclerosis
and cardiovascular pathologies caused by it are readily recognized and treated as inflammatory diseases [45]. Practically all cardiovascular risk factors are to a different extent linked to inflammation, while inflammation itself is recognized as a cardiovascular risk factor [46,47].

The participation of dietary polyphenols in the modulation of inflammation and how this could contribute to the reduction of cardiovascular risk was recently discussed [48]. There is a growing body of evidence on the anti-inflammatory activities of cocoa polyphenols. The protective role of cocoa in CVD inflammation has been considered in a number of human intervention studies, and numerous in vitro studies have also been carried out, led by an interest in disclosing the mechanisms and identifying the agents responsible for the anti-inflammatory cardio-protective activities of cocoa. Accordingly, polyphenols have been proposed as principal anti-inflammatory mediators. In this review, we aim to summarize these findings in order to assess the effects of cocoa polyphenols on cardiovascular-related inflammation.

2. Cocoa Polyphenols

Polyphenols in cocoa beans could contribute to about 12%–18% of the dry weight [49], making them practically inedible due to the bitterness and astringency [50]. Wollgast and Anklam [51] reported that catechins, anthocyanins, and proanthocyanidins constitute about 37%, 4% and 58% of cocoa bean polyphenols, respectively. Flavanols are the most important class of cocoa polyphenols [51,52]. They are presented by monomers ((+)- and (−)-isomers of catechin and epicatechin and their derivatives) and build-up of (epi)catechin subunit polymers (proanthocyanidins) [53]. Phenolic acids, flavonols and their glycosides, some stilbenes, simple phenols, and isocoumarins are also present in minor amounts [54–56]. Cyanidin-3-α-L-arabinoside and cyanidin-3-β-D-galactoside have been reported to be principal anthocyanins of cocoa, however, mainly in unprocessed fresh beans [51]. (−)-Epicatechin constitutes about 35% of the total phenolic content of cocoa beans, while other catechins, such as (+)-catechin, (+)-gallocatechin, and (−)-epigallocatechin, are present in smaller quantities. Dimers (B1, B2, B3, B4 and B5), trimers (C1), and oligomers (tetramer D) of flavan-3,4-diols, linked by 4→8 or 4→6 bounds (B-type linkage), represent the main cocoa polymers, procyanidins [53,57,58]. The structures of the main cocoa polyphenols, monomeric and polymeric flavanols, are shown in Figure 1. Some other procyanidins have been identified in smaller amounts in fresh cocoa beans: dodecamer and three A-type (2→7 or 2→5 along with 4β→8 linkage) procyanidin dimmers [53,59] probably derive from oxidative conversion of B-type procyanidins [60,61]. In general, unfermented (fresh) cocoa beans contain flavanols with a varied range of polymerization, from monomers up to decamers [62].

The polyphenol content of cocoa could vary up to 4-fold depending on different varieties [63] and origins [64]. In addition to the above factors, cocoa beans undergo several steps of primary and secondary processing due to which the ratio and types of polyphenols found in cocoa beans are different from those found in the finished products [65]. For instance, the processes of fermentation and alkalization reduce the polyphenol content [63,66–68] and, consequently, the antioxidant activity of cocoa beans [32,67]. Thus, (−)-epicatechin and (+)-catechin decrease depending on the extent of cocoa bean fermentation: unfermented, partly fermented or fully fermented. In addition, high temperatures and long duration of processing also decrease the polyphenol content [51,68,69]. Some
special methodological adjustments could be applied in order to prevent cocoa polyphenols from oxidation during different stages of cocoa processing, increasing their content in a final product [70,71].

Figure 1. (I) Main cocoa flavanol monomers: (+)-catechin; (−)-epicatechin; (II) Main cocoa flavanol polymers: (a–e)—dimers: procyanidin B1, B2, B3, B4, B5, respectively; (f)—trimer: procyanidin C1; (g)—tetramer: procyanidin D.

Semi-finished products such as cocoa liquor, and cocoa butter and cocoa powder derived from it, which are manufactured during secondary processing, are usually used in manufacturing final cocoa products (e.g., cocoa powder and chocolate) [72]. Sometimes unprocessed cocoa bean powder is introduced, mainly in order to enrich the polyphenol content of the final product [50,73]. The content of polyphenols in the final product is defined by the amount and type of cocoa components. Thus, cocoa powder is shown to have higher polyphenol content than cocoa butter [39,74], since it is mainly the low-fat solid component of cocoa nibs. Non-fat cocoa solids (NFCS) are considered to represent the total phenolic content in cocoa products [75]. Based on NFCS, cocoa powder represents the highest phenolic content (72%–87%), followed by baking chocolate (45%–49%), dark chocolate (20%–30%), semi-sweet chocolate (15%–19%), and milk chocolate (5%–7%) [76]. The quantitative determination of polyphenol content in a cocoa product can be assessed by using either total polyphenols [31] or the
measurements of (−)-epicatechin and (+)-catechin [26], and also B-type procyanidin contents [73]. Based on weight in grams, (−)-epicatechin and (+)-catechin content follows a decreasing order, cocoa powder > dark chocolate > milk chocolate [77], while each content could be widely variable. For example, for cocoa powder it can range from 116.02 to 730.26 μg/g for (−)-epicatechin, and from 81.40 to 447.62 μg/g for (+)-catechin, the total monomeric content ranging from 182.84 to 1066.13 μg/g [68]. In general, according to the polyphenol database Phenol-Explorer [78], the mean values of (−)-epicatechin and (+)-catechin are about 158 and 107, 70 and 20, and 15 and 5 mg/100 g FW in cocoa powder, dark chocolate, and milk chocolate, respectively. However, the amount of consumed cocoa polyphenols would also depend on serving size, thus, in a normal diet, dark chocolate would provide more polyphenols than other cocoa products [39].

As a consequence of whole processing, cocoa-derived products mainly contain less bioavailable (−)-catechin enantiomer, in contrast to cocoa beans and most foods that contain (+)-catechin [79,80]. Analyses of polyphenols have shown a relative abundance of oligomers and individual components in cocoa liquor, which follows the order: monomers > trimers > dimers > tetramers and epicatechin > procyanidin B2 > procyanidin C1 > catechin, respectively [81]. The trend in cocoa powder was different and followed the order: monomers > dimers > trimers > tetramers and epicatechin > catechin > procyanidin B2 > procyanidin C1, respectively [81]. Trace amounts of gallocatechin and epigallocatechin [55] and quercetin aglycone as well as some quercetin glycosides have been identified in cocoa liquor and cocoa powder [56,82]. Some additional flavonoids, such as naringenin, luteolin, apigenin and some glycosides of these compounds, and quercetin-glucuronide were also reported [68,77].

On the whole, during cocoa processing the polyphenol content is reduced more than ten times [74,83], with the undesirable bitter and astringent taste diminishing sometimes in final cocoa products. Cocoa food products existing on the market are characterized by highly diverse polyphenol content, mainly due to the differences in cocoa processing and product manufacturing, in addition to intrinsic geographical and genetic plant divergence [61,73,77,84]. Epidemiological and clinical studies on the health benefits of cocoa polyphenols should account for this variability in addition to other aspects, such as the bioavailability of putatively bioactive cocoa polyphenols, which we will discuss in the following section.

3. Bioavailability of Cocoa Polyphenols

In order to provide conclusive evidence for the effectiveness of cocoa polyphenols in disease prevention and human health improvement, it is essential to determine the nature and distribution of these compounds in our diet. In addition, the bioavailability of the ingested cocoa polyphenols will circumscribe organism exposure to these putatively bioactive compounds, affecting a magnitude of related health outcomes. There are a number of factors influencing the bioavailability of cocoa polyphenols, starting from their dietary consumption and finishing with their fate in the human organism.

The daily consumption of cocoa catechins and proanthocyanidins depends on cultural and regional dietary habits [75]. It has been estimated that in some regions (e.g., Belgium/Luxemburg) cocoa product consumption could reach up to 6 kg in cocoa beans/person per annum, the world average being 0.55 kg/person per annum [85]. The majority of intervention and cross-sectional studies regarding the
health effects of cocoa have been conducted using cocoa beverages or chocolate as the most habitually used cocoa products [86], therefore bioavailability and intervention studies have also been focused mainly on these cocoa products. The protagonists of these studies are the major cocoa flavanols, epicatechin and procyanidins, since they have so far been foreseen as the principal bioactive cocoa polyphenols due to both their abundance and their relevance to biological activities and physicochemical structures [49,87,88].

Upon ingestion of cocoa products in doses close to habitual diet monomeric and polymeric cocoa flavanols are rapidly absorbed. Thus, it was shown that procyanidins and monomers could be detected in plasma as early as 0.5 h and maximal plasma concentration of these compounds was reached at about 2 h after ingestion [89–100]. The plasmatic T_{max} of detected cocoa flavanols did not normally exceed 3 h, and their elimination from plasma in most cases was already achieved 6 h after cocoa consumption [94–96]. However, some epicatechin metabolites could have a delayed appearance and could remain in systemic circulation for up to 24 h, suggesting their intestinal microbiota catabolic origin [97,98]. Rapid plasmatic appearance suggests that the detected polyphenols are mainly absorbed in the small intestine. This was ratified by the data coming from in vitro and in vivo bioavailability studies on catechins and procyanidins [99,101,102]. However, absorption of flavan-3-ols in the small intestine is not complete, and depends not only on flavanol chemistry, but also on their structural isomerism and stereoisomerism [103]. Therefore, epicatechins and catechins were shown to have different levels of absorption [93,94], and plasma concentration of (+) and (−) forms of catechin were found to be different after cocoa product consumption [79,104]. The level of absorption, furthermore, depends on the range of polymerization, which will also limit their bioavailability [49]. In vitro studies suggested that flavanols only up to trimers were able to pass through the small intestine [101,102]. In humans, only traces of procyanidin B2 were detected in human plasma after ingestion of cocoa products [93,94]. More complex flavanols appeared to be stable under acidic conditions mimicking stomach digestion [105], so that, being unabsorbed in the small intestine, they are transited to the large intestine, where they are subjected to catabolic activities of intestinal microbiota [106].

Under absorption in the gastrointestinal tract, cocoa flavanols (monomers) are recognized by the organism as xenobiotics and are extensively transformed into various metabolites [107]. (−)-Epicatechin in its sulfate, glucuronides or methyl conjugated forms were the main forms representing about 33%, 28%, and 33% of total epicatechin metabolites in human plasma and urine [97], the most relevant being (−)-epicatechin-3′-β-d-glucuronide, (−)-epicatechin 3′-sulfate, 3′-O-methyl-(−)-epicatechin sulfates [97,108]. In fact, epicatechin aglycone was undetectable both in plasma and urine according to recent findings, where advanced methods were applied [97,108].

Due to the gastrointestinal and hepatic metabolism, the conjugated metabolites are destined to be rapidly eliminated from the human body. Cocoa flavanols, absorbed in the small intestine, are normally cleared from the body over 24 h, like the majority of dietary polyphenols. On the other hand, a large proportion of unabsorbed flavanols, e.g., polymers and monomers, are subjected to colonic microflora catabolic activities [106,109,110]. Consequently, low-molecular-weight microbiota catabolites of these flavanols are absorbed from the colon, belatedly emerging in systemic circulation as phase II conjugates [106,107,111]. Valerolactones and valeric acids were reported to be first-step microbiota-derived catabolites [106,112] of unabsorbed small intestine epicatechin and procyanidins [112–115], whereas various phenolic acids were identified as intermediate and last-step
products of microbial flavanol catabolism [106,111,113,116]. On the other hand, a part of unabsorbed flavanols can accumulate in the low digestive tract and are finally excreted from the human body with faeces [106,117,118]. Plasmatic concentrations vary widely among reported flavanol microbiota metabolites, some of them reaching micromolar levels in response to cocoa polyphenol consumption [114]. The studies in human urine have not only indicated the bioavailability but also demonstrated the importance of the phase II conjugated metabolites and some colonic microbiota metabolites as promising biomarkers of cocoa consumption [119–121], justifying their application for dietary compliance control in cocoa intervention studies along with hydrolyzed epicatechin [114,122–124].

Recently, the scientific community has become aware that the microbe-derived metabolites of polyphenols represent a large proportion of dietary polyphenol intake [106,125–128], impacting on their bioavailability and potentially exhibiting some bioactive effects [129–132]. Moreover, regular consumption of polyphenol-rich cocoa could in turn influence the colonic bacterial population and metabolic activities [133], enlarging inter-individual flavanol bioavailability variation [134]. For example, a significant difference in bacterial metabolite profiles between regular cocoa product consumers and non-consumers was reported in response to dark chocolate intervention [135]. Nowadays, microbial cocoa metabolites are being reconsidered with regard to their health-related bioactivities, including those related to CVD inflammation, which we will address later in the corresponding section.

The interaction between different nutrients, the food matrix and texture are one of several important factors that affect the bioavailability of cocoa polyphenols. The effect of milk, the most commonly used food element in cocoa-formulated products, on the bioavailability of both primary cocoa polyphenols and their host and microbiota metabolites has been studied with different cocoa products [96,113,136–140]. However, conclusions on this issue have remained controversial. In addition, carbohydrates and proteins [141–143], along with the complex food matrix and cocoa product physical stage (liquid vs. solid) [144,145], were also considered to interfere in the mechanism of flavanol uptake, affecting the bioaccessibility and bioavailability of cocoa polyphenols in human subjects.

Although in the majority of the intervention studies the doses of cocoa products were close to high rather than average in habitual consumption, systemically circulating (plasmatic) concentrations of cocoa flavanols were reported to be relatively low—from nano- to micro-molar range for epicatechin and not always detected nano-molar concentrations for procyanidins [95,98,100,146]. Low maximum concentration (C_max), a short half-life, extensive metabolic conjugation and rapid excretion, all add up to relatively low cocoa polyphenol bioavailability, compromising their relevance for health effects and bioactivities reported in in vitro and in vivo mechanistic studies [147]. On the other hand, there are data showing that sustained chronic consumption of cocoa products can lead to a relatively low but significant accumulation of cocoa polyphenols in human plasma [148], sufficient to exert some health-relevant bioactivity. These data support the idea that high doses of cocoa polyphenols might not always be needed to manifest biological activities, and the time of interaction could also be important.

The absorption of cocoa polyphenols, characterized as epicatechin 24 h urinary recovery data, was considered to be poor, reaching not more than 30% of the total ingested (−)-epicatechin both with chocolate and with cocoa powder [97,98]. Some studies reported much lower recoveries [96,103],
especially when the cocoa polyphenol doses were closer to habitual dietary consumption and cocoa products were co-administrated with milk [96]. The participation of procyanidins in epicatechin bioavailability due to catabolic activities of colonic microflora is still being questioned due to the controversy in reported data [108,115]. Data on cocoa polyphenol absorption did not account for microbial-derived metabolites. So far, addressing this issue has proved challenging, since the majority of identified microbiota flavanol catabolites are not epicatechin specific and could also be related to other dietary polyphenols and/or unrelated microbial activities [106].

Although levels of circulating cocoa polyphenol metabolites appeared to be dose dependent [95,100], high inter-individual variability, mainly defined by individual metabolic phenotypes [149,150], was reported in practically all bioavailability studies. On the other hand, large inter-individual differences in colonic flavanol bioconversion, attributed to the individual colonic microbiota composition, are also expected to have an impact on variation in the bioavailability of cocoa polyphenols [127,134]. Such variability is difficult to control on the population level due to the nature of its matter; therefore, it still remains one of the main concerns in interventional studies regarding polyphenols’ health-benefiting activities, as it compromises the accurate estimation and correct interpretation of studied outcomes.

4. Cocoa Polyphenols and CVD Inflammatory Markers

Evidence from several epidemiological studies has demonstrated the favorable association of cocoa and its derived products with a lower risk of CVD mortality [33,40,151]. Thus, the effect of high cocoa consumption in Kuna Indians who lived in their indigenous islands in Panama has been related to lower blood pressure and low mortality rates as compared to Kunas emigrated to the urban areas of Panama City, revealing its favorable effect [152]. In the Dutch Zutphen Study, in a cohort of elderly men, high cocoa intake was related to lower blood pressure and was inversely associated with cardiovascular and all-cause mortality [33]. In Women’s Health Study, chocolate intake was also found to be inversely associated with cardiovascular mortality, along with other foods rich in flavonoids, such as some fruits and red wine [153].

Although the mechanism for the beneficial effects of cocoa and its derived products still remains to be fully elucidated, the potential biological role of flavanols has been suggested by various human interventions [36,38–40] and in vitro/in vivo mechanistic studies [39–41]. So far, among the most relevant impacts of cocoa polyphenols on cardiovascular health should be highlighted their effect on the most significant markers of CVD: oxLDL [124,154,155], lipid profile [124,154,156], blood pressure [35,157,158], nitric oxide [52,159], hemostasis [91,148,160] and endothelial dysfunction [159,161,162].

Thus, it is well known that alteration in plasma cholesterol levels (LDL-c and HDL-c) is related to the progression of atherosclerosis and CVD [163]. Dietary medium-term intervention with cocoa powder in mild hypercholesterolemic subjects showed significantly lower levels of LDL-c [164], while the level of HDL-c was found to be increased in normo- and mild hyper-cholesterolemic subjects after dark chocolate or cocoa powder consumption [154,164,165]. A recent study in women affected by normal weight obese syndrome, which is characterized by a higher risk of cardiovascular morbidity and mortality, suggested that regular consumption of dark chocolate had favorable effects on HDL-c, lipoprotein ratios and inflammation markers [166]. Oxidized LDLs play a crucial role in the
progression of atherosclerosis [167]. There are several studies that have established oxidized low-density lipoprotein (oxLDL) as a useful marker for cardiovascular diseases [168–171]. Cocoa polyphenols have been shown to decrease the oxidation of LDL in \textit{in vitro} studies [172,173]. In addition, intervention studies have demonstrated that isolated LDLs are less prone to \textit{in vitro} oxidation after the consumption of various cocoa products [154,155,174–176]. Moreover, a recent study including 42 high-risk human subjects reported a significant decrease in plasma oxLDL levels in addition to a significant increase in plasma HDL-c concentration after chronic cocoa consumption [124]. The role of cocoa polyphenols has also been investigated for their effect on vascular systems, which could lead to reduced risk of CVD. The main targets include nitric oxide (NO) concentration and endothelial function, along with decreased susceptibility of LDL to oxidation and inhibition of platelet activation and aggregation [155,177,178]. In numerous studies, which were recently reviewed [179], both acute and sustained consumption of flavanol-containing cocoa products were reported to have a dose-dependent beneficial effect on endothelial function via an improvement in FMD. An increase in the plasma nitric oxide (NO) concentration has been shown in healthy subjects after the consumption of cocoa beverages containing different contents of flavanols. This change in plasma NO-modulated FMD indicates an association between increased bioavailability of NO and improved endothelial function [180]. Cocoa polyphenols from dietary sources may also improve endothelial functions by augmenting NO-synthase activity [52,159,181,182], leading to a decrease in systolic and diastolic blood pressure [162,183,184]. Platelet aggregation occurs during the initiation of coronary thrombosis and several studies support evidence about the potent activity of cocoa polyphenols as inhibitors of platelet aggregation and adhesion, thus reducing clot formation [185,186].

Cardiovascular pathology is accompanied by chronic low-intensity inflammation, involving the participation of a variety of cells (endothelial, smooth muscular, monocytes, lymphocytes and platelets), adhesion molecules (selectins, integrins and immunoglobulin superfamily molecules), cytokines (pro-inflammatory and anti-inflammatory), chemokines, growth factors and enzymes (metalloproteases, cyclooxygenases and lipooxygenases) [187]. These inflammatory mediators appear to play a key role in each step of atherogenesis, starting from the initial phases of leukocyte recruitment, to the eventual rupture of the vulnerable atherosclerotic plaque [44]. Some of these key players are often used in the evaluation of a grade of pathological changes or response to treatment, usually referring to them as CVD-related inflammatory markers [188]. Apart from this, inflammation itself is considered a risk factor for CVD [187,189,190]. Therefore, circulating levels of the inflammatory markers could also reflect the current inflammatory state of the individuals, exhibiting their risk status in respect of CVD. The accumulated evidence on the health benefits of cocoa for disorders of a chronic inflammatory nature, such as CVD, prompted the need to focus on the association between bioactive cocoa polyphenols and inflammatory mediators of CVD, with the purpose of identifying and recognizing factors involved and mechanisms underlying this interaction.

4.1. Human Studies

Up until now, only one epidemiologic study has reported on the relationship between cocoa consumption and inflammation. Thus, a large cohort study involving men and women randomly recruited from the general population demonstrated a J-shaped relationship between dark chocolate
consumption and serum hs-CRP, a CVD inflammatory marker. Those subjects who usually consumed up to 1 serving (20 g) of dark chocolate every 3 days had significantly lower serum hs-CRP concentrations than non-consumers [191]. Most of the evidence on the possible interaction between cocoa polyphenols and CVD-related inflammation was obtained in clinical intervention studies involving human subjects. The human intervention studies evaluating the effect of cocoa polyphenols on inflammatory mediators of CVD are presented in Table 1.

As well as the above-mentioned epidemiological study, CRP (C-reactive protein), a biomarker strongly associated with coronary heart disease and inflammation [192], was evaluated in several clinical trials with cocoa (Table 1). However, only a few of these studies reported on changes in CRP levels due to cocoa consumption. Thus, one of the first intervention trials performed by Mathur [176] and Kurlandsky [193] reported no changes in hs-CRP circulation in healthy subjects due to medium-term intervention with dark chocolate. However, a decrease in the CRP systemic levels of healthy subjects was observed after short- and medium-term daily consumption of cocoa beverages in two recent studies [194,195]. The decrease in circulating CRP was shown to be linear in response to the polyphenol content of the consumed cocoa beverages, according to the data from the latest study [195].

It is worth noting that both studies had crossover designs with well-matched treatment controls (adjusted for other important cocoa bioactive compounds, such as theobromine and caffeine), which reinforce the evidence on the role of cocoa polyphenols in this interaction. A short-term intervention study reported on specific gender changes in hs-CRP upon dark chocolate consumption observed in healthy female but not male volunteers [196]. However, these findings should be confirmed in a bigger, controlled matched intervention on a well-recruited female population to avoid any impact of hormonal status during the menstrual cycle on systemic inflammation [197]. In contrast to crossover studies on healthy subjects, no impact of cocoa consumption was observed on the hs-CRP level in subjects with compromised cardiovascular health in the few available studies [123,198,199]. Thus, in a medium-term crossover study with hypertensive pre-diabetic subjects, dark chocolate consumption was compared to white chocolate with an impact on certain CVD markers, including circulating levels of CRP. Although authors reported a beneficial effect of medium-term consumption of dark chocolate on vascular function, insulin sensitivity, and BP in hypertensive patients, no effects were observed on the hs-CRP level [199]. No change in hs-CRP levels was detected either in subjects at high cardiovascular risk in another crossover study after chronic cocoa powder in milk intake [123]. A parallel arm intervention study [198], involving patients with coronary artery disease, reports that over a 6-week period, flavanol-rich cocoa does not modify vascular function in patients with established CAD. Along with vascular functions evaluated postprandially (90 min) and after chronic consumption (3 and 6 weeks), circulating hs-CRP was evaluated. However, it was not affected either by acute or chronic consumption of cocoa-derived products.
Table 1. Human intervention studies considering the relationship between cocoa polyphenols and cardiovascular disease (CVD)-related inflammatory markers (studies are presented in chronological order). Ref. = Reference.

| Intervention                                                                 | Comparison | Population | Markers of Dietary Compliance | Cocoa Consumption Impact                                      | Ref. |
|------------------------------------------------------------------------------|------------|------------|-------------------------------|----------------------------------------------------------------|------|
| **Cocoa Source (dose)**                                                     |            |            |                               | 2 h postprandial:                                               |      |
| High- vs. Low-procyanidin chocolate (37 g/dose)                             | High-procyanidin chocolate: 148 mg tot. Pr       | H vs. L                | 2 h plasma (BM)              | ↓leukotriene/prostacyclin ratio                                 | [89] |
|                                                                             | Low-procyanidin chocolate: 3.3 mg tot. Pr        |                        | 6 h plasma (BM)              | ↓leukotrienes (C4 + D4 + E4) ↑prostacyclins                   |      |
| Dark chocolate + cocoa beverage (36.9 g + 30.95 g/day)                      | Chocolate (daily):                                | Before/After            | Plasma (tot. PPh)             | No effect: IL-1beta, IL-6, TNF-α, hs-CRP, P-selectin         | [176]|
| (6 weeks)                                                                   | 168.3 mg Pr                                      | 25                      |                               |                                                                |      |
|                                                                             | Cocoa beverage (daily):                           |                          |                               |                                                                |      |
|                                                                             | 483.1 mg Pr                                       |                        |                               |                                                                |      |
| Dark chocolate (41 g/day)                                                   | Before/After DC vs. Ctrl group                    | 10                      | NA                            | ↓ICAM-1                                                        | [193]|
| (6 weeks)                                                                   |                                                       |                        |                               | No effect: VCAM-1 and hs-CRP                                  |      |
| Chocolate and cocoa beverage (48 g chocolate + 18 g cocoa beverage/day)    | Flavanol group (daily):                           | Before/After             | NA                            | No effect (acute or chronic): ICAM-1, VCAM-1, E- and P-selectins and hs-CRP | [198]|
| (90 min)                                                                    | 444 mg flavanols                                  | 40                      | Coronary artery disease (CAD) |                                                                |      |
|                                                                             | 107 mg epicatechin                                 |                          | NA                            |                                                                |      |
|                                                                             | Control group (daily):                             |                          |                               |                                                                |      |
|                                                                             | 19.6 mg flavanols                                  |                          |                               |                                                                |      |
|                                                                             | 4.7 mg epicatechin                                  |                          |                               |                                                                |      |
| Low- and High-flavanol cocoa beverages (36 g powder (18.8 g cocoa per 240 mL W) | Before/After                                       | 32                      | Fasting plasma (BM)           | ↓sVCAM-1(High-flavanol group)                                  | [200]|
| (6 weeks)                                                                   | High-flavanol group:                               |                          |                               | No effect: ICAM-1; E- and P-selectins                         |      |
|                                                                             | 446 mg tot. flavanols                              |                          |                               |                                                                |      |
|                                                                             | Low-flavanol group:                                |                          |                               |                                                                |      |
|                                                                             | 43 mg tot. flavanols                               |                          |                               |                                                                |      |
| Dark chocolate 70% (100 g/day)                                              | Daily: 700 mg flavonoids                           | Before/After             | NA                            | ↓hs-CRP (females only, n = 19)                                 | [196]|
| (7 days)                                                                    |                                                       | 28                      |                               | No effect: hs-CRP (common group)                              |      |
| Nutrients 2014, 6 | 855 |
|-----------------|-----|

**Table 1. Cont.**

| Treatment | MTI Duration | CO | Dietary Intake | Before/After | Study Population | Baseline | Effect |
|-----------|--------------|----|----------------|--------------|-----------------|----------|--------|
| Dark chocolate (50 g/day × 2 times/day) | MTI (15 days) | CO | Dark chocolate (daily): 1008 mg tot. PPh 110.9 mg epicatechin 36.12 mg catechin White chocolate (daily): 0.13 g tot. PPh 0.04 mg catechin | DC vs. WC (Ctrl) 19 | Hypertensive prediabetic | NA | No effects: hs-CRP [199] |
| Cocoa beverage (31 g/150 mL W × 2 times/day) | MTI (2 weeks) | CO | Flavanol beverage (daily): 451 mg tot. PPh 57 mg epicatechin 31 mg catechin 338 mg Pr Control beverage (daily): 14 mg tot. PPh 1 mg epicatechin 4 mg catechin 8 mg Pr | Before/After Flavanol vs. Control beverage (Ctrl) 20 | Hypertensive Fasting plasma (BM) | No effect: TNF-α, IL-6, MCP-1, E-selectin, VCAM-1, and ICAM-1 [201] |
| Cocoa powder (20 g/250 mL M × 2 times/day) | MTI (4 weeks) | CO | Daily: 40.41 mg (+)-catechin 46.08 mg (−)-epicatechin 36.54 mg procyanidin B2 495.2 mg tot. PPh 425.7 mg tot. Pr | Cocoa (CM) vs. M (Ctrl) 42 | CVD high risk Fasting plasma (BM) 24 h urine (BM) | ↓ VLA-4, CD40, CD36 (monocytes) ↓ P-selectin and ICAM-1 (serum) Non-significant changes: ↓ VCAM-1 and MCP-1 No effect: hs-CRP, IL-6, E-selectin [123] |
| High- and Low-cocoa flavanol beverage (NA) | MTI (4 weeks) | CO | High-cocoa flavanol (daily): 494 mg tot. Flavanols Low-cocoa flavanol (daily): 23 mg tot. Flavanols | Before/After H vs. L 20 | Healthy Fasting plasma (BM) 24 h urine (BM) | ↓ CRP (High-cocoa flavanol group) [194] |
Table 1. Cont.

| Cocoa beverages (daily): | L, M, H vs. Control beverage (Ctrl) | 20 | Obese healthy | NA | ↓CRP | ↓IL-6 | [195] |
|--------------------------|-------------------------------------|----|---------------|----|------|-------|-------|
| Cocoa powder (40 g/250 mL M or W) | CO | AI (6 h) | Daily: 40.41 mg (+)-catechin | Before/After | 18 | Healthy | 2 h plasma (BM) | ↓NF-κB | ↓E-selectin | ↓ICAM-1 | [203] |
| Cocoa product rich in fibre (15 g/200 mL M × 2 times/day) | CO | MTI (4 weeks) | 13.9 mg/g soluble PPh | Cocoa vs. M (Ctrl) | 24 | Healthy and Hypercholesterolemic subjects | NA | ↓IL-1β, IL-10 | No effect: IL-6, TNF-α, MCP-1, VCAM and ICAM | [156] |
| Dark chocolate 70% (100 g/day) | NC | STI (7 days) | Before/After | 15 | Normal weight obese women | NA | ↓ICAM-1 | ↓IL-1Ra and ↓E-selectin | [202] |
| Dark chocolate 70% (25 g × 2 times/day) | NC | MTI (4 weeks) | Daily: 2135 mg PPh | Before/After | 20 | Hypertensive (excess body weight) | NA | Non-significant changes: | | | |
| Cocoa beverages (daily): | L, M, H vs. Control beverage (Ctrl) | 20 | Obese healthy | NA | ↓CRP | ↓IL-6 | [195] |
| Cocoa beverages (daily): | L, M, H vs. Control beverage (Ctrl) | 20 | Obese healthy | NA | ↓CRP | ↓IL-6 | [195] |
| Cocoa beverages (daily): | L, M, H vs. Control beverage (Ctrl) | 20 | Obese healthy | NA | ↓CRP | ↓IL-6 | [195] |

AI—acute intervention; BM—biomarkers for dietary compliance (e.g., phase II epicatechin metabolites and/or total epicatechin or total flavanols); C—cocoa; CO—crossover design; CRP—C-reactive protein; hs-CRP—high sensitivity C-reactive protein; Ctrl—control; DC—dark chocolate; ICAM-1, Intercellular Adhesion Molecule-1; IL-6, Interleukin-6; M—Milk; MCP-1—Monocyte Chemoattractant Protein-1; MTI—medium-term intervention; NC—no control design; PA—parallel arm design; PPh—polyphenols; STI—short-term intervention; VCAM-1—Vascular Cell Adhesion Molecule-1; VLA-4—Very Late Activation Antigen-4; W—water; WC—white chocolate.
The differences in the circulating levels of cell adhesion molecules may reveal a stage for pathophysiological events due to activation or damage to various cells [204–206]. Some studies with solid designs (crossover and parallel arm), involving both healthy and unhealthy subjects, were not able to detect cocoa intake-provoked changes in the circulation of key adhesion molecules such as ICAM-1 and VCAM-1 [156,195,198,201]. However, some other studies reported a positive impact of cocoa consumption on the different types of CVD inflammation-related adhesion molecules. Thus, in a group of postmenopausal hypercholesterolemic women consuming a high-flavanol cocoa beverage (446 mg of total flavanols), there was a 2.4-fold increase in hyperemic blood flow associated with a significant decrease in plasma levels of VCAM-1, compared to the low-flavanol cocoa beverage group (43 mg of total flavanols). However, no differences were seen for E- and P-selectins, along with ICAM-1 [200]. On the other hand, no significant changes were observed for VCAM-1, but circulating ICAM-1 concentrations significantly decreased after consumption of dark chocolate (41 g/day) by healthy subjects [193]. A study performed by Monagas and colleagues suggests that the chronic consumption of cocoa powder may modulate the expression of adhesion molecules (soluble and expressed on T-cell and monocyte surfaces) related to the early stages of atherosclerosis in subjects at high risk of coronary heart disease. In a randomized crossover medium-term feeding trial they demonstrated a lower serum concentration of P-selectin and ICAM-1 and decreased expression of cell adhesion molecules (very late activation antigen-4 (VLA-4), CD40, and CD36) on the monocyte surface after intervention with cocoa powder in skimmed milk (C + M) vs. only skimmed milk ingestion (M). The circulating levels of VCAM-1 and MCP-1 concentrations were also lower, but not statistically significant, while that of E-selectin remained unchanged after C+M compared with M intake [123]. Their results agreed with the previously reported decrease in ICAM-1 in healthy volunteers due to chronic dark chocolate consumption [193]. However, for the first time a positive effect of cocoa consumption on P-selectin concentrations was reported by Monagas and colleagues, in contrast to previous results obtained on both healthy [176] and health-compromised subjects [198,200].

Nuclear factor κB (NF-κB) is a key molecule in the pathophysiology of atherosclerosis involved in the regulation of adhesion molecules and cytokine expression [207]. A recent crossover study on healthy subjects evaluated the effect of acute cocoa consumption in different matrices related to the bioavailability of cocoa polyphenols in NF-κB activation and the expression of adhesion molecules [203]. The administration of 40 g of cocoa powder either with milk (CM) or water (CW) decreased ICAM concentration 6 h after intake, while E-selectin levels were lower only after CW intervention, with no changes in VCAM-1 concentration either with CM or CW interventions. Acute consumption of cocoa with water (CW) significantly decreased NF-κB activation in peripheral blood monocytes compared to baseline and to CM [203], whereas milk treatment alone (control) significantly induced NF-κB activation. On the other hand, cocoa mixed with milk had no effects on NF-κB activation. The observed differences were attribute to the different bioavailability of polyphenolic compounds present in cocoa powder when taken with milk or water, which was monitored during the study as urinary host phase II (epicatechin-Glucs and -Sulfs) and microbial (sum of the 3,4-dihydroxyphenylacetic, protocatechuic, 4-hydroxybenzoic, 4-hydroxyhippuric, hippuric, caffeic and ferulic acids) metabolites [203]. Therefore, it was suggested that cocoa consumption could confer beneficial anti-inflammatory effects mediated by inhibition of the NF-κB-dependent transcription pathway or interaction with certain cytokines and the food matrix can modulate this effect.
Interleukins are thought to be involved in the chronic inflammatory response that is typical of atherosclerosis [206]. A one-week regular consumption of dark chocolate (100 g/day) in normal weight obese women showed a significant reduction in the serum level of the interleukin-1 receptor antagonist (IL-1Ra) and its positive correlation with total cholesterol, LDL cholesterol and CVD risk indexes changes. A neutral effect on other pro-inflammatory cytokine (IL-1α, IL-1β, IL-6, and TNF-α) and hs-CRP levels was reported [166]. Similar results were obtained for inflammatory markers including TNF-α, IL-1β, IL-6 and P-selectin along with hs-CRP in a non-controlled clinical trial, which failed to find any changes in interleukins in healthy subjects upon consumption of polyphenol-rich cocoa supplements, consisting of dark chocolate (36.9 g/day) and cocoa powder (30.95 g/day) for 6 weeks [176]. However, a recent crossover study [156] on normo- and hyper-cholesterolemic subjects demonstrated the decreased serum level of IL-1β and IL-10 after regular 4-week consumption of cocoa products with milk (15 g twice per day) as compared to control (milk). Other measured parameters such as IL-6, TNF-α, IL-8, MCP-1, and vascular and intracellular cell adhesion molecule levels remained unchanged [156].

Recently, leukotrienes (LTs) have been implicated as mediators, biomarkers, and possible therapeutic targets in the context of subclinical atherosclerosis [208]. Leukotrienes are arachidonic acid (AA)-derived lipid mediators of inflammation, exerting a range of pro-inflammatory effects, and have proved to be important mediators in inflammatory conditions such as preclinical atherosclerosis. For this reason, it has been suggested that leukotriene synthesis inhibitors and leukotriene receptor antagonists induce beneficial effects at preclinical stages of the atherosclerotic process [209]. Data from an early short-term crossover intervention study suggest that cocoa polyphenols can favourably alter eicosanoid synthesis in humans, providing a plausible hypothesis for a mechanism by which they can decrease platelet activation in humans [89]. Thus, the consumption of high-procyanidin chocolate resulted in increased prostacyclin and decreased leukotriene concentrations, and, as result, in a decreased leukotriene-prostacyclin ratio, a measure of the pro-inflammatory/anti-inflammatory eicosanoid balance [89].

Although the majority of human studies provide evidence for a possible interaction between cocoa polyphenols and inflammatory mediators involved in CVD, practically all of them warn about certain limitations and appeal for further, better designed intervention studies to confirm the presented outcomes. Overall, in order to determine the biological effect of cocoa polyphenols and to reach any beneficial conclusion that could possibly be implemented in human health, large-scale randomized placebo-controlled studies are required to confirm and expand upon the potential anti-inflammatory role of polyphenol-rich cocoa products. Moreover, the design of human intervention trials should use a relevant amount of cocoa products, which corresponds to real-life doses and could readily be incorporated into the regular human diet.

4.2. Animal Models, in Vitro and Cell Culture Studies

There are not many in vivo animal studies specifically focused on the CVD-related activity of cocoa polyphenols, and even fewer considering inflammatory mediators [41]. However, as demonstrated by human studies, animal intervention studies also support the capability of cocoa polyphenols to effectively suppress the production of cytokines and adhesion molecules that promote CVD-related
inflammation. In a recent study by Gu and colleagues [210], male mice previously fed with a high-fat (HF) diet for 8 weeks were randomized to a HF diet or HF diet supplemented with 8% cocoa powder (HF–HFC group) for 10 weeks. Cocoa supplementation significantly decreased the plasma levels of the pro-inflammatory mediators, IL-6 (30.4%) and the expression of several pro-inflammatory genes (Il6, Il12b, Nos2, and Emr1) in mice. Moreover, unlike the study reported by Monagas and colleagues [123] in humans, the above study also demonstrated a significant decrease in MCP-1, after cocoa supplementation.

It is noteworthy that the composition of chocolate or cocoa differing in polyphenol contents and dietary doses could lead to different outcomes in CVD risk endpoints [211,212]. Most of the human intervention studies using chocolate or cocoa powder supplementation have reported a protective effect related to systemic inflammation. On the other hand, a recent study by Yakala et al. [213] demonstrated the unfavorable effect of chocolate consumption on cardiovascular parameters. In this study, the effects of chocolate supplementation were studied in ApoE*3-Leiden mice, a model susceptible to diet-induced atherosclerosis, fed with a high-cholesterol control diet supplemented with two different chocolates (A and B), where chocolate A had a relatively high-polyphenol and low-fibre content compared to chocolate B. After both chocolate treatments, an increase in plasma cholesterol and atherosclerotic plaque formation was observed, compared to the mice fed only with a high-cholesterol diet. In addition, mice on a high-cholesterol diet supplemented with chocolate B showed elevated plasma levels of VCAM-1 and E-selectin, whereas the chocolate A showed no effects. Supplementation with chocolate A appeared to be less unfavorable than chocolate B with respect to inflammatory parameters, which was related to the higher circulating polyphenol concentrations present in the A group. Therefore, the discrepancies reported in this study were attributed to the difference in the polyphenol composition of chocolate and quantity consumed. In contrast to the chocolate intervention, a recent study reported that a 7-day high-cocoa diet (4.8 g/kg/day) reduced the production of pro-inflammatory cytokines (IL-6 and TNF-α), along with the production of NO and reactive oxygen species, in rat peritoneal macrophages ex vivo [214]. However, no significant changes were found in this study when a lower (2.4 g/kg/day) cocoa diet was applied.

In comparison to animal models, in vitro and cell culture models were more extensively applied in research on the CVD anti-inflammatory properties of cocoa polyphenols.

Table 2 represents the studies regarding the effects of cocoa polyphenols on inflammatory mediators discussed previously for human intervention studies. The in vitro and cell culture experiments were originally appointed to help identify cellular and molecular targets for the anti-inflammatory activities of cocoa polyphenols.
**Table 2. In vitro studies on cocoa polyphenol CVD-related anti-inflammatory activities. Ref. = Reference.**

| Model | Treatment (dose) | Outcomes | Ref. |
|-------|------------------|----------|------|
| **Leukotrienes** | | | |
| (a) Isolated rabbit 15-LOX-1 (b) Recombinant human platelet 12-LOX | (a) Cocoa procyanidins: monomers to decamers (2.9 mg/mL) (b) Epicatechin & procyanidin decamers | Dose-dependent: (a) ↓ 15-LOX-1 activity (b) ↓ 12-LOX activity | [215] |
| Recombinant human 5-LOX | Cocoa epicatechin & procyanidins (10 μmol/L) | ↓ 5-LOX activity | [216] |

**Pro-Inflammatory and Anti-Inflammatory Cytokines**

| Model | Treatment (dose) | Outcomes | Ref. |
|-------|------------------|----------|------|
| PHA-stimulated PBMC | Cocoa procyanidins: monomers through decamers (25 μg/mL) | ↓ IL-1β secretion (monomer to tetramer) ↑ IL-1β secretion (pentamer to decamer) ↓ IL-2 expression (pentamer to heptamer) ↓ IL-4 expression & secretion (pentamer to decamer) | [217] |
| Human PBMC | Cocoa procyanidins: monomers through decamers (25 μg/mL) | ↑ IL-1β transcription & secretion (pentamers-decamers) ↓ IL-1β transcription & secretion (monomers-tetramers) | [218] |
| Resting and (PHA)-stimulated human PBMC | Cocoa procyanidins: monomers through decamers (25 μg/mL) | ↑ IL-4 secretion (hexamer-decamer fraction) PHA-stimulated PBMCs: ↑ IL-4 secretion (monomeric fraction) ↓ IL-4 secretion (hexamer-decamer fraction) | [219] |
| Resting and (PHA)-stimulated human PBMC | CFP fractions: monomers through decamers (25 μg/mL) | ↓ TNF-α (monomers and dimers) ↑ TNF-α (tetramers through octamers) | [220] |
| PHA-stimulated PBMC | Cocoa flavanols and their related oligomers (25 μg/mL) | ↓ IL-5 release (oligomeric fractions: hexamers to decamers) | [221] |
| Rat NR8383 macrophages | Cocoa polyphenol extract (10–50 μg/mL tot. PPh) vs. epicatechin (30–60 μg/mL tot. PPh) | ↓ TNF-α, MCP-1, IL-1α, IL-6) | [222] |
### Table 2. Cont.

**Pro-Inflammatory and Anti-Inflammatory Cytokines**

| Cell Type                          | Treatment                                                                 | Effect(s)                                      | Reference |
|-----------------------------------|---------------------------------------------------------------------------|------------------------------------------------|-----------|
| Murine EL4BOU6 lymphocytes        | Cocoa extract (5–80 μg/mL tot. PPh) vs. epicatechin (60–120 μg/mL tot. PPh) | ↓IL-2 secretion, ↑IL-4 secretion, ↓T lymphocyte activation | [223]     |
| Human PBMC                        | Cocoa flavanol fractions: Short (monomers-pentamers)                        | ↑IL-1β, IL-6, IL-10, TNF-α (long-chain fraction) | [224]     |
|                                   | Long-chain (hexamers-decamers) (20 μg/mL)                                  |                                                 |           |
| LPS-stimulated human PBMC         | Cocoa phenolic acids: (3,4-DHPPA, 3-HPA, 3,4-DHPAA, 3-HPAA, 4-HBA) (1 μM) | ↓TNF-α, ↓IL-6, ↑IL-1β                           | [225]     |
| Jurkat T cells                    | Purified cocoa: [(-)-epicatechin (EC) and (+)-catechin (CT)] and a B dimeric procyandinin (DP-B) (1.7–17.2 μM) | ↓NF-κB, ↓IL-2 transactivation                  | [226]     |

4-DHPAA—3,4-dihydroxyphenylacetic acid; 3,4-DHPPA—3,4 dihydroxyphenylpropionic acid; 3-HPA—3-hydroxyphenylpropionic acid; 3-HPAA—3-hydroxyphenylacetic acid; 4-HBA—4-hydroxybenzoic acid; CFP—Cocoa flavanols preparation; LOX—lipoxygenase; MCP-1—monocyte chemoattractant protein-1; PBMC—peripheral blood mononuclear cells; PHA—phytohemagglutinin; VSMC—vascular smooth muscle cells.
It has been shown that cocoa polyphenols can inhibit lipoxigenase activity in vitro [215,216]. Inflammatory mediators, leukotrienes, are formed via the 5-lipoxygenase pathway of arachidonic acid metabolism; therefore, cocoa polyphenols might modulate leukotrienes via eicosanoid metabolism [180]. Schewe and colleagues [215,216] reported that cocoa (−)-epicatechin and its low-molecular procyanidins inhibit both dioxygenase and LTA(4) synthase activities of human 5-LOX, the first two consecutive steps in the conversion of arachidonic acid into leukotrienes. Moreover, epicatechin and procyanidin decamer inhibited the recombinant human platelet 12-LOX. They suggested that this mechanism may underlie a putative anti-inflammatory effect of cocoa products. Thus, their outcomes are in line with the results from the in vivo study, where healthy subjects had lower levels of the plasma leukotrienes LTC4, LTD4 and LTE4, along with increased levels of prostacyclin, 2 h after procyanidin-rich chocolate consumption [89].

Intervention studies suggest that dietary cocoa polyphenols may modulate atherogenic inflammatory processes via interaction with cytokines. Several in vitro studies have studied the immunomodulatory effects of cocoa polyphenols on the production of cytokines in human peripheral blood mononuclear cells (Table 2). Thus, studies performed by Mao and colleagues [217–221] demonstrated that some fraction of cocoa polyphenols may exhibit anti-inflammatory activities by modulating the production of pro-inflammatory cytokines, including IL-1β, IL-2, IL-6 and TNF-α, and secretion of the anti-inflammatory cytokine IL-4 [219]. The nature and extent of this modulation were strongly dependent on the degree of polymerization of the tested procyanidins. Thus, smaller fractions of cocoa polyphenols (monomers-tetramers) consistently decreased pro-inflammatory IL-1β expression, while the larger oligomers (pentamers-decamers) increased its expression [218]. Ramiro and colleagues also reported that cocoa extract and epicatechin mediated a decrease in the secretion and RNA expression of various pro-inflammatory mediators by macrophages, such as MCP-1, TNF-α, IL-1α, and IL-6 mRNA expressions, suggesting that a cocoa polyphenol inhibitory effect on cytokine secretion is produced, in part, at the transcriptional level [222]. However, a striking increase in the LPS-induced synthesis of IL-1β, IL-6, IL-10, and TNF-α in the presence of long-chain flavanols from cocoa by mononuclear cells was demonstrated in another in vitro study [224]. Epicatechin and cocoa extract were also shown to significantly reduce IL-2Rα (CD25) expression and IL-2 secretion on activate peripheral blood mononuclear cells [223]. In resting and PHA-stimulated PBMC, the intermediate-sized cocoa flavanol and procyanidin fractions (tetramers to octamers) were shown to display an increase in TNF-α secretion. The monomers and dimers were slightly inhibitory, while trimers, nonamers and decamers induced TNF-α levels [220]. Cocoa flavanols and their related oligomers were also able to modulate IL-5 in PHA-stimulated peripheral blood mononuclear cells [221].

A study reported the effect of cocoa microbial-derived phenolic acids (3,4 dihydroxyphenylpropionic acid (3,4-DHPPA), 3-hydroxyphenylpropionic acid, 3,4-dihydroxyphenylacetic acid (3,4-DHPAA), 3-hydroxyphenylacetic acid, 4-hydroxybenzoic acid and 4-hydroxyhippuric acid (4-HHA)) on the modulation of the production of pro-inflammatory cytokines, i.e., TNF-α, IL-1β and IL-6, in LPS-stimulated PBMC [225]. The phenolic acids used were at a biological concentration level (1 mM) within the range (0.1–10 mM) found in plasma samples after cocoa polyphenol intake [227]. Only the dihydroxylated compounds, 3,4-DHPPA and 3,4-DHPAA, with the exception of 4-HHA for TNF-α secretion, significantly inhibited the secretion of these pro-inflammatory cytokines. The concentrations of IL-6 were reduced with 3,4-DHPPA and 3,4-DHPAA pretreatment. This study demonstrated that
dihydroxylated phenolic acids derived from colonic microbial metabolites could probably act as an anti-inflammatory agent, providing favourable effects on CVD [225].

**NF-κB** is a redox-sensitive transcription factor that regulates the expression of large family of genes, including those encoding proteins involved in inflammation such as IL-1, IL-6, and TNF-α [228]. Flavanols have been shown to modulate the inflammatory effect in cultured RAW264.7 murine macrophages via NF-κB pathways, and this depended on the degree of polymerization [229]. Thus, monomers and dimers repressed the TNF-α secretion and NF-κB-dependent gene expression induced by interferon γ, whereas the procyanidin C2 enhanced them. Epicatechin monomers were also shown to interact with NF-κB and inhibit TNF-α-stimulated activation of T lymphocytes [226]. Epicatechin and procyanidins can inhibit NF-κB at different levels in the activation pathways, where the decrease in cell oxidants that are involved in NF-κB activation and the prevention of NF-κB activation via specific interaction with signaling proteins are seen as main mechanisms [230]. On the whole, the results from these studies demonstrate that cocoa polyphenols can act as modulators of the immune response in immune cells involved in the early stages of atherogenic inflammation.

Although only a few studies have been carried out, animal experiments are expected to contribute much to the mechanistic understanding of the role of cocoa polyphenols in CVD inflammatory processes. However, these models have certain limitations that should be considered while interpreting results and extrapolating them to humans: type and dose for intervention, model vs. human-specific metabolism, etc. Regarding *in vitro* and cell culture studies, the main concern is the type of cocoa polyphenols applied for treatment. Since in CVD-related inflammatory research models usually represent the processes normally occurring close to systemic circulation (immune cells, vascular and endothelial tissues), the main compounds considered in these interactions should be bioavailable metabolites of polyphenols, mainly presented as phase II host and microbial metabolites of epicatechin. In addition, it is difficult to make an alignment between doses of polyphenols tested in *in vitro* models and those normally related to dietary consumption in humans.

5. Conclusions

The data from clinical and experimental studies considered in this review suggest that cocoa products, due to its high polyphenol content, may exert anti-inflammatory properties. Yet much remains to be elucidated on the interaction of cocoa polyphenols with inflammatory mediators involved in cardiovascular pathology. Larger, well-designed, placebo-controlled studies are expected to approach this question. At this point, there is a certain need to address recently raised new aspects regarding cocoa polyphenol bioavailability in future investigations. One of them is the role of cocoa polyphenol metabolites in respect of their anti-inflammatory properties. Cocoa polyphenol bioavailability depends on numerous varying components, which are sometimes difficult to control in clinical and population studies. To get a better approximation of the association between cocoa polyphenol consumption and its health outcomes, a detailed monitoring of cocoa polyphenol bioavailability during intervention studies is required. Two main groups of metabolites should be considered, both in human and in model studies: host and microbiota-derived metabolites. Recent human studies have already started to account for these metabolites, not only as dietary compliance biomarkers, but also to assess their impact on human health [156,166,202,203,210,214]. This is also
supported by the fact that polyphenol microbial metabolites can exert various biological activities, some of them with anti-inflammatory potential [106,123,225]. The role of phase II conjugation is another issue to be considered, especially in mechanistic studies on cocoa polyphenol bioactivities, e.g., their anti-inflammatory properties. Both host and microbial metabolites are mainly present as phase II conjugates in systemic circulation upon dietary intake of cocoa products. Therefore, they are principal forms of cocoa polyphenols available for targeting the inflammatory process in vivo. Being distinct from core compounds in their properties, these metabolites warrant being considered as principal mediators in cocoa CVD-related anti-inflammatory activities. On the other hand, a possible intracellular deconjugation metabolism of phase II metabolites, as was recently reported in a case with resveratrol [231], should also be considered and investigated in detail for cocoa polyphenols.

Acknowledgments

The authors are grateful for the support granted by the following Spanish government programmes: CICYT AGL2009-13906-C02-01, AGL2010-10084-E and FUN-C Food CSD2007-063 from the Ingenio-CONSOLIDER programme of the Spanish Government. The postdoctoral contract fellowship, awarded by the Ministry of Innovation and Science to Olha Khymenets and Sara Tulipani (Juan de la Cierva Program), and the predoctoral fellowships awarded by the Generalitat de Catalunya (FI-DRG) to Ximena Mora-Cubillos and Mar Garcia-Aloy are acknowledged. Mireia Urpí-Sardà and Rafael Llorach would like to thank Ramon y Cajal Program of the Spanish Ministry (MINECO) and the Fondo Social Europeo.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Global Status Report on Noncommunicable Diseases 2010; World Health Organization: Geneva, Switzerland, 2011.
2. Lloyd-Jones, D.; Adams, R.J.; Brown, T.M.; Carnethon, M.; Dai, S.; de Simone, G.; Ferguson, T.B.; Ford, E.; Furie, K.; Gillespie, C.; et al. Heart disease and stroke statistics—2010 update: A report from the American Heart Association. Circulation 2010, 121, e46–e215.
3. Mathers, C.D.; Loncar, D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006, 3, e442.
4. Halfon, N.; Hochstein, M. Life course health development: An integrated framework for developing health, policy, and research. Milbank Q. 2002, 80, 433–479.
5. Ben-Shlomo, Y.; Kuh, D. A life course approach to chronic disease epidemiology: Conceptual models, empirical challenges and interdisciplinary perspectives. Int. J. Epidemiol. 2002, 31, 285–293.
6. Wang, D.; He, Y.; Li, Y.; Luan, D.; Zhai, F.; Yang, X.; Ma, G. Joint association of dietary pattern and physical activity level with cardiovascular disease risk factors among Chinese men: A cross-sectional study. PLoS One 2013, 8, e66210.
7. Chomistek, A.K.; Manson, J.E.; Stefanick, M.L.; Lu, B.; Sands-Lincoln, M.; Going, S.B.; Garcia, L.; Allison, M.A.; Sims, S.T.; LaMonte, M.J.; et al. Relationship of sedentary behavior and physical activity to incident cardiovascular disease: Results from the Women’s Health Initiative. *J. Am. Coll. Cardiol.* **2013**, *61*, 2346–2354.

8. Chomistek, A.K.; Cook, N.R.; Flint, A.J.; Rimm, E.B. Vigorous-intensity leisure-time physical activity and risk of major chronic disease in men. *Med. Sci. Sports Exerc.* **2012**, *44*, 1898–1905.

9. Salehi-Abargouei, A.; Maghsoudi, Z.; Shirani, F.; Azadbakht, L. Effects of Dietary Approaches to Stop Hypertension (DASH)-style diet on fatal or nonfatal cardiovascular diseases-incidence: A systematic review and meta-analysis on observational prospective studies. *Nutrition* **2013**, *29*, 611–618.

10. He, M.; van Dam, R.M.; Rimm, E.; Hu, F.B.; Qi, L. Whole-grain, cereal fiber, bran, and germ intake and the risks of all-cause and cardiovascular disease-specific mortality among women with type 2 diabetes mellitus. *Circulation* **2010**, *121*, 2162–2168.

11. De Moura, F.F.; Lewis, K.D.; Falk, M.C. Applying the FDA definition of whole grains to the evidence for cardiovascular disease health claims. *J. Nutr.* **2009**, *139*, 2220S–2226S.

12. Nettleton, J.A.; Steffen, L.M.; Loehr, L.R.; Rosamond, W.D.; Folsom, A.R. Incident heart failure is associated with lower whole-grain intake and greater high-fat dairy and egg intake in the Atherosclerosis Risk in Communities (ARIC) study. *J. Am. Diet. Assoc.* **2008**, *108*, 1881–1887.

13. Dauchet, L.; Ferrieres, J.; Arveiler, D.; Yarnell, J.W.; Gey, F.; Ducimetiere, P.; Ruidavets, J.B.; Haas, B.; Evans, A.; Bingham, A.; et al. Frequency of fruit and vegetable consumption and coronary heart disease in France and Northern Ireland: The PRIME study. *Br. J. Nutr.* **2004**, *92*, 963–972.

14. Dauchet, L.; Montaye, M.; Ruidavets, J.B.; Arveiler, D.; Kee, F.; Bingham, A.; Ferrieres, J.; Haas, B.; Evans, A.; Ducimetiere, P.; et al. Association between the frequency of fruit and vegetable consumption and cardiovascular disease in male smokers and non-smokers. *Eur. J. Clin. Nutr.* **2010**, *64*, 578–586.

15. Scalbert, A.; Johnson, I.T.; Saltmarsh, M. Polyphenols: Antioxidants and beyond. *Am. J. Clin. Nutr.* **2005**, *81*, 215S–217S.

16. Arts, I.C.; Hollman, P.C. Polyphenols and disease risk in epidemiologic studies. *Am. J. Clin. Nutr.* **2005**, *81*, 317S–325S.

17. Bhupathiraju, S.N.; Tucker, K.L. Greater variety in fruit and vegetable intake is associated with lower inflammation in Puerto Rican adults. *Am. J. Clin. Nutr.* **2011**, *93*, 37–46.

18. Clifton, P.M. Effect of grape seed extract and quercetin on cardiovascular and endothelial parameters in high-risk subjects. *J. Biomed. Biotechnol.* **2004**, *2004*, 272–278.

19. Aviram, M.; Rosenblat, M.; Gaitini, D.; Nitecki, S.; Hoffman, A.; Dornfeld, L.; Volkova, N.; Presser, D.; Attias, J.; Liker, H.; et al. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. *Clin. Nutr.* **2004**, *23*, 423–433.

20. George, T.W.; Niwat, C.; Waroonphan, S.; Gordon, M.H.; Lovegrove, J.A. Effects of chronic and acute consumption of fruit- and vegetable-puree-based drinks on vasodilation, risk factors for CVD and the response as a result of the eNOS G298T polymorphism. *Proc. Nutr. Soc.* **2009**, *68*, 148–161.
21. Duthie, S.J.; Jenkinson, A.M.; Crozier, A.; Mullen, W.; Pirie, L.; Kyle, J.; Yap, L.S.; Christen, P.; Duthie, G.G. The effects of cranberry juice consumption on antioxidant status and biomarkers relating to heart disease and cancer in healthy human volunteers. *Eur. J. Nutr.* **2006**, *45*, 113–122.

22. Franke, A.A.; Cooney, R.V.; Henning, S.M.; Custer, L.J. Bioavailability and antioxidant effects of orange juice components in humans. *J. Agric. Food Chem.* **2005**, *53*, 5170–5178.

23. Naruszewicz, M.; Laniewska, I.; Millo, B.; Dluzniewski, M. Combination therapy of statin with flavonoids rich extract from chokeberry fruits enhanced reduction in cardiovascular risk markers in patients after myocardial infraction (MI). *Atherosclerosis* **2007**, *194*, e179–e184.

24. Source: UNCTAD Based on the Data from International Cocoa Organization, Quarterly Bulletin of Cocoa Statistics). Available online: http://www.unctad.info/en/Infocomm/Beverages/Cocoa2/Market/ (accessed on 10 August 2013).

25. Lee, K.W.; Kim, Y.J.; Lee, H.J.; Lee, C.Y. Cocoa has more phenolic phytochemicals and a higher antioxidant capacity than teas and red wine. *J. Agric. Food Chem.* **2003**, *51*, 7292–7295.

26. Vinson, J.A.; Proch, J.; Zubik, L. Phenol antioxidant quantity and quality in foods: Cocoa, dark chocolate, and milk chocolate. *J. Agric. Food Chem.* **1999**, *47*, 4821–4824.

27. Lea, A.G.H. The Procyanidins of Cocoa. In Proceedings of the American Chemical Society Meeting, Denver, CO, USA, 5–10 April 1987.

28. Lea, A.G.H.; Ford, G.D. *The Polyphenols of Cocoa Part I: Isolation and Characterisation of Procyanidins from Unfermented Beans*; The Cadbury Schweppes Group: London, UK, 1988.

29. Lea, P.J.; Ford, G.D. *Characterisation of the Polyphenols of Cocoa*; Bioflavour: Glasgow, UK, 1990.

30. Niemenak, N.; Rohsius, C.; Elwers, S.; Ndoumou, D.O.; Lieberei, R. Comaparative study of different cocoa (*Theobroma cacao* L.) clones in terms of their phenolics and anthocyanins contents. *J. Food Compos. Anal.* **2006**, *19*, 612–619.

31. Waterhouse, A.L.; Shirley, J.R.; Donovan, J.L. Antioxidants in chocolate. *Lancet* **1996**, *348*, 834.

32. Adamson, G.E.; Lazarus, S.A.; Mitchell, A.E.; Prior, R.L.; Cao, G.; Jacobs, P.H.; Kremers, B.G.; Hammerstone, J.F.; Rucker, R.B.; Ritter, K.A.; *et al*. HPLC method for the quantification of procyanidins in cocoa and chocolate samples and correlation to total antioxidant capacity. *J. Agric. Food Chem.* **1999**, *47*, 4184–4188.

33. Buijsse, B.; Feskens, E.J.; Kok, F.J.; Kromhout, D. Cocoa intake, blood pressure, and cardiovascular mortality: The Zutphen Elderly Study. *Arch. Intern. Med.* **2006**, *166*, 411–417.

34. Janszky, I.; Mukamal, K.J.; Ljung, R.; Ahnve, S.; Ahlbom, A.; Hallqvist, J. Chocolate consumption and mortality following a first acute myocardial infarction: The Stockholm Heart Epidemiology Program. *J. Intern. Med.* **2009**, *266*, 248–257.

35. Ried, K.; Sullivan, T.R.; Fakler, P.; Frank, O.R.; Stocks, N.P. Effect of cocoa on blood pressure. *Cochrane Database Syst. Rev.* **2012**, *8*, CD008893.

36. Hooper, L.; Kay, C.; Abdelhamid, A.; Kroon, P.A.; Cohn, J.S.; Rimm, E.B.; Cassidy, A. Effects of chocolate, cocoa, and flavan-3-ols on cardiovascular health: A systematic review and meta-analysis of randomized trials. *Am. J. Clin. Nutr.* **2012**, *95*, 740–751.

37. Jia, L.; Liu, X.; Bai, Y.Y.; Li, S.H.; Sun, K.; He, C.; Hui, R. Short-term effect of cocoa product consumption on lipid profile: A meta-analysis of randomized controlled trials. *Am. J. Clin. Nutr.* **2010**, *92*, 218–225.
38. Hooper, L.; Kroon, P.A.; Rimm, E.B.; Cohn, J.S.; Harvey, I.; le Cornu, K.A.; Ryder, J.J.; Hall, W.L.; Cassidy, A. Flavonoids, flavonoid-rich foods, and cardiovascular risk: A meta-analysis of randomized controlled trials. *Am. J. Clin. Nutr.* 2008, 88, 38–50.

39. Visioli, F.; Bernaert, H.; Corti, R.; Ferri, C.; Heptinstall, S.; Molinari, E.; Poli, A.; Serafini, M.; Smit, H.J.; Vinson, J.A.; *et al.* Chocolate, lifestyle, and health. *Crit. Rev. Food Sci. Nutr.* 2009, 49, 299–312.

40. Corti, R.; Flammer, A.J.; Hollenberg, N.K.; Luscher, T.F. Cocoa and cardiovascular health. *Circulation* 2009, 119, 1433–1441.

41. Rimbach, G.; Melchin, M.; Moehring, J.; Wagner, A.E. Polyphenols from cocoa and vascular health—A critical review. *Int. J. Mol. Sci.* 2009, 10, 4290–4309.

42. Libby, P. Inflammation in atherosclerosis. *Arterioscler. Thromb. Vasc. Biol.* 2012, 32, 2045–2051.

43. Packard, R.R.; Libby, P. Inflammation in atherosclerosis: From vascular biology to biomarker discovery and risk prediction. *Clin. Chem.* 2008, 54, 24–38.

44. Hansson, G.K. Inflammatory mechanisms in atherosclerosis. *J. Thromb. Haemost.* 2009, 7, 328–331.

45. Willerson, J.T.; Ridker, P.M. Inflammation as a cardiovascular risk factor. *Circulation* 2004, 109, II2–II10.

46. Kaplan, R.C.; Frishman, W.H. Systemic inflammation as a cardiovascular disease risk factor and as a potential target for drug therapy. *Heart Dis.* 2001, 3, 326–332.

47. Tangney, C.C.; Rasmussen, H.E. Polyphenols, inflammation, and cardiovascular disease. *Curr. Atheroscler. Rep.* 2013, 15, 324.

48. Bravo, L. Polyphenols: Chemistry, dietary sources, metabolism, and nutritional significance. *Nutr. Rev.* 1998, 56, 317–333.

49. Harwood, M.L.; Ziegler, G.R.; Hayes, J.E. Tolerance for high flavanol cocoa powder in semisweet chocolate. *Nutrients* 2013, 5, 2258–2267.

50. Wollgast, J.; Anklam, E. Review on polyphenols in theobroma cacao: Changes in composition during the manufacture of chocolate and methodology for identification and quantification. *Food Res. Int.* 2000, 33, 423–447.

51. Schroeter, H.; Heiss, C.; Balzer, J.; Kleinbongard, P.; Keen, C.L.; Hollenberg, N.K.; Sies, H.; Kwik-Uribe, C.; Schmitz, H.H.; Kelm, M. (−)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. *Proc. Natl. Acad. Sci. USA* 2006, 103, 1024–1029.

52. Porter, L.J.; Ma, Z.; Chan, B.G. Cacao procyanidins: Major flavonoids and identification of some minor metabolites. *Phytochemistry* 1991, 30, 1657–1663.

53. Hurst, W.J.; Glinski, J.A.; Miller, K.B.; Apgar, J.; Davey, M.H.; Stuart, D.A. Survey of the trans-resveratrol and trans-piceid content of cocoa-containing and chocolate products. *J. Agric. Food Chem.* 2008, 56, 8374–8378.

54. Lamuela-Raventos, R.M.; Andres-Lacueva, C.; Pernyayer, J.; Izquierdo-Pulido, M. More antioxidants in cocoa. *J. Nutr.* 2001, 131, 834–835.
56. Sanchez-Rabaneda, F.; Jauregui, O.; Casals, I.; Andres-Lacueva, C.; Izquierdo-Pulido, M.; Lamuela-Raventos, R.M. Liquid chromatographic/electrospray ionization tandem mass spectrometric study of the phenolic composition of cocoa (Theobroma cacao). J. Mass Spectrom. 2003, 38, 35–42.
57. Qin, Y.Z.; Holt, R.R.; Lazarus, S.A.; Ensunsra, J.L.; Hammerstone, J.F.; Schmitz, H.H.; Keen, C.L. Stability of flavan-3-ols epicatechin and catechin and related dimeric procyanidins derived from cocoa. J. Agric. Food Chem. 2002, 50, 1700–1705.
58. Santos-Buelga, C.; Scalbert, A. Proanthocyanidins and tannin-like compounds—Nature, occurrence, dietary intake and effects on nutrition and health. J. Sci. Food Agric. 2000, 80, 1094–1117.
59. Hammerstone, J.F.; Lazarus, S.A.; Mitchell, A.E.; Rucker, R.; Schmitz, H.H. Identification of procyanidins in cocoa (Theobroma cacao) and chocolate using high-performance liquid chromatography/mass spectrometry. J. Agric. Food Chem. 1999, 47, 490–496.
60. Tanaka, T.; Kondou, K.; Kouo, I. Oxidation and epimerization of epigallocatechin in banana fruits. Phytochemistry 2000, 53, 311–316.
61. Zhu, Q.Y.; Hammerstone, J.F.; Lazarus, S.A.; Schmitz, H.H.; Keen, C.L. Stabilizing effect of ascorbic acid on flavan-3-ols and dimeric procyanidins from cocoa. J. Agric. Food Chem. 2003, 51, 828–833.
62. Kelm, M.A.; Johnson, J.C.; Robbins, R.J.; Hammerstone, J.F.; Schmitz, H.H. High-performance liquid chromatography separation and purification of cacao (Theobroma cacao L.) procyanidins according to degree of polymerization using a diol stationary phase. J. Agric. Food Chem. 2006, 54, 1571–1576.
63. Clapperton, J.; Lockwood, R.; Romanczyk, L.; Hammerstone, J.F. Contribution of genotype to cocoa (Theobroma cacao L.) flavour. Trop. Agric. 1994, 71, 303–308.
64. Azizah, O.; Amin, I.; Nawalyah, A.G.; Ilham, A. Antioxidant capacity and phenolic content of cocoa beans. Food Chem. 2007, 100, 1523–1530.
65. Cooper, K.A.; Campos-Gimenez, E.; Jimenez Alvarez, D.; Nagy, K.; Donovan, J.L.; Williamson, G. Rapid reversed phase ultra-performance liquid chromatography analysis of the major cocoa polyphenols and inter-relationships of their concentrations in chocolate. J. Agric. Food Chem. 2007, 55, 2841–2847.
66. Kim, H.; Keeney, P.G. (−)-Epicatechin content in fermented and unfermented cocoa beans. J. Food Sci. 1984, 49, 1090–1092.
67. Robinson, T.; Ranalli, A.W.; Phillips, A.W. Changes in cocoa tannins during processing. J. Agric. Food Chem. 1961, 9, 295–298.
68. Andres-Lacueva, C.; Monagas, M.; Khan, N.; Izquierdo-Pulido, M.; Urpi-Sarda, M.; Pernanyer, J.; Lamuela-Raventos, R.M. Flavanol and flavonol contents of cocoa powder products: Influence of the manufacturing process. J. Agric. Food Chem. 2008, 56, 3111–3117.
69. Kyi, T.M.; Wan Ramli, W.D.; Abu Bakar, M.; Mohd. Wahid, S.; Abdul Amir, H.K.; Meor Zainal, M.T. The kinetics of polyphenol degradation during the drying of malaysian cocoa beans. Int. J. Food Sci. Technol. 2005, 40, 323–331.
70. Payne, M.J.; Hurst, W.J.; Miller, K.B.; Rank, C.; Stuart, D.A. Impact of fermentation, drying, roasting, and Dutch processing on epicatechin and catechin content of cacao beans and cocoa ingredients. J. Agric. Food Chem. 2010, 58, 10518–10527.
71. Hurst, W.J.; Krake, S.H.; Bergmeier, S.C.; Payne, M.J.; Miller, K.B.; Stuart, D.A. Impact of fermentation, drying, roasting and Dutch processing on flavan-3-ol stereochemistry in cacao beans and cocoa ingredients. *Chem. Cent. J.* **2011**, *5*, 53.

72. Hii, C.L.; Law, C.L.; Suzannah, S.; Misnawi; Cloke, M. Polyphenols in cocoa (*Theobroma cacao* L.). *Asian J. Food Agro Ind.* **2009**, *5*, 702–722.

73. Gu, L.; House, S.E.; Wu, X.; Ou, B.; Prior, R.L. Procyanidin and catechin contents and antioxidant capacity of cocoa and chocolate products. *J. Agric. Food Chem.* **2006**, *54*, 4057–4061.

74. De Brito, E.S.; Garcia, N.H.P.; Gallao, M.I.; Cortelazzo, A.L.; Fevereiro, P.S.; Braga, M.R. Structural and chemical changes in cocoa (*Theobroma Cacao*) during fermentation, drying and roasting. *J. Sci. Food Agric.* **2000**, *81*, 281–288.

75. Cooper, K.A.; Donovan, J.L.; Waterhouse, A.L.; Williamson, G. Cocoa and health: A decade of research. *Br. J. Nutr.* **2008**, *99*, 1–11.

76. Miller, K.B.; Stuart, D.A.; Smith, N.L.; Lee, C.Y.; McHale, N.L.; Flanagan, J.A.; Ou, B.; Hurst, W.J. Antioxidant activity and polyphenol and procyanidin contents of selected commercially available cocoa-containing and chocolate products in the United States. *J. Agric. Food Chem.* **2006**, *54*, 4062–4068.

77. Miller, K.B.; Hurst, W.J.; Flannigan, N.; Ou, B.; Lee, C.Y.; Smith, N.; Stuart, D.A. Survey of commercially available chocolate- and cocoa-containing products in the United States. 2. Comparison of flavan-3-ol content with nonfat cocoa solids, total polyphenols, and percent cacao. *J. Agric. Food Chem.* **2009**, *57*, 9169–9180.

78. Neveu, V.; Perez-Jimenez, J.; Vos, F.; Crespy, V.; du Chaffaut, L.; Mennen, L.; Knox, C.; Eisner, R.; Cruz, J.; Wishart, D.; *et al.* Phenol-Explorer: An online comprehensive database on polyphenol contents in foods. *Database* **2010**, *2010*, bap024.

79. Donovan, J.L.; Crespy, V.; Oliveira, M.; Cooper, K.A.; Gibson, B.B.; Williamson, G. (+)-Catechin is more bioavailable than (−)-catechin: Relevance to the bioavailability of catechin from cocoa. *Free Radic. Res.* **2006**, *40*, 1029–1034.

80. Kofink, M.; Papagiannopoulos, M.; Galensa, R. (−)-Catechin in cocoa and chocolate: Occurrence and analysis of an atypical flavan-3-ol enantiomer. *Molecules* **2007**, *12*, 1274–1288.

81. Natsume, M.; Osakabe, N.; Yamagishi, M.; Takizawa, T.; Nakamura, T.; Miyatake, H.; Hatano, T.; Yoshida, T. Analyses of polyphenols in cacao liquor, cocoa, and chocolate by normal-phase and reversed-phase HPLC. *Biosci. Biotechnol. Biochem.* **2000**, *64*, 2581–2587.

82. Andrés-Lacueva, C.; Lamuela-Raventós, R.M.; Jáuregui, O.; Casals, I.; Izquierdo-Pulido, M.; Permanyer, J. An LC method for the analysis of cocoa phenolics. *LC GC Eur.* **2000**, *12*, 902–904.

83. Bonvehi, J.S.; Coll, F.V. Evaluation of the bitterness and astringency of polyphenolic compounds in cocoa powder. *Food Chem.* **1997**, *60*, 365–370.

84. Stahl, L.; Miller, K.B.; Apgar, J.; Sweigart, D.S.; Stuart, D.A.; McHale, N.; Ou, B.; Kondo, M.; Hurst, W.J. Preservation of cocoa antioxidant activity, total polyphenols, flavan-3-ols, and procyanidin content in foods prepared with cocoa powder. *J. Food Sci.* **2009**, *74*, C456–C461.

85. Emmanuel Ohene Afoakwa. *Chocolate Science and Technology*; Wiley-Blackwell: Hoboken, NJ, USA, 2010.
Arranz, S.; Valderas-Martinez, P.; Chiva-Blanch, G.; Casas, R.; Urpi-Sarda, M.; Lamuela-Raventos, R.M.; Estruch, R. Cardioprotective effects of cocoa: Clinical evidence from randomized clinical intervention trials in humans. *Mol. Nutr. Food Res.* **2013**, *57*, 936–947.

Heim, K.E.; Tagliaferro, A.R.; Bobilya, D.J. Flavonoid antioxidants: Chemistry, metabolism and structure-activity relationships. *J. Nutr. Biochem.* **2002**, *13*, 572–584.

Corcoran, M.P.; McKay, D.L.; Blumberg, J.B. Flavonoid basics: Chemistry, sources, mechanisms of action, and safety. *J. Nutr. Gerontol. Geriatr.* **2012**, *31*, 176–189.

Schramm, D.D.; Wang, J.F.; Holt, R.R.; Ensunsa, J.L.; Gonsalves, J.L.; Lazarus, S.A.; Schmitz, H.H.; German, J.B.; Keen, C.L. Chocolate procyanidins decrease the leukotriene-prostacyclin ratio in humans and human aortic endothelial cells. *Am. J. Clin. Nutr.* **2001**, *73*, 36–40.

Rein, D.; Lotito, S.; Holt, R.R.; Keen, C.L.; Schmitz, H.H.; Fraga, C.G. Epicatechin in human plasma: in vivo determination and effect of chocolate consumption on plasma oxidation status. *J. Nutr.* **2000**, *130*, 2109S–2114S.

Holt, R.R.; Lazarus, S.A.; Sullards, M.C.; Zhu, Q.Y.; Schramm, D.D.; Hammerstone, J.F.; Fraga, C.G.; Schmitz, H.H.; Keen, C.L. Procyanidin dimer B2 [epicatechin-(4β-8)-epicatechin] in human plasma after the consumption of a flavanol-rich cocoa. *Am. J. Clin. Nutr.* **2002**, *76*, 798–804.

Richelle, M.; Tavazzi, I.; Enslen, M.; Offord, E.A. Plasma kinetics in man of epicatechin from black chocolate. *Eur. J. Clin. Nutr.* **1999**, *53*, 22–26.

Mullen, W.; Borges, G.; Donovan, J.L.; Edwards, C.A.; Serafini, M.; Lean, M.E.; Crozier, A. Milk decreases urinary excretion but not plasma pharmacokinetics of cocoa flavan-3-ol metabolites in humans. *Am. J. Clin. Nutr.* **2009**, *89*, 1784–1791.

Actis-Goretta, L.; Leveques, A.; Giuffrida, F.; Romanov-Michailidis, F.; Viton, F.; Barron, D.; Duenas-Paton, M.; Gonzalez-Manzano, S.; Santos-Buelga, C.; Williamson, G.; et al. Elucidation of (−)-epicatechin metabolites after ingestion of chocolate by healthy humans. *Free Radic. Biol. Med.* **2012**, *53*, 787–795.

Baba, S.; Osakabe, N.; Yasuda, A.; Natsume, M.; Takizawa, T.; Nakamura, T.; Terao, J. Bioavailability of (−)-epicatechin upon intake of chocolate and cocoa in human volunteers. *Free Radic. Res.* **2000**, *33*, 635–641.

Actis-Goretta, L.; Leveques, A.; Rein, M.; Teml, A.; Schafer, C.; Hofmann, U.; Li, H.; Schwab, M.; Eichelbaum, M.; Williamson, G. Intestinal absorption, metabolism, and excretion of (−)-epicatechin in healthy humans assessed by using an intestinal perfusion technique. *Am. J. Clin. Nutr.* **2013**, *98*, 924–933.
100. Wang, J.F.; Schramm, D.D.; Holt, R.R.; Ensunsa, J.L.; Fraga, C.G.; Schmitz, H.H.; Keen, C.L. A dose-response effect from chocolate consumption on plasma epicatechin and oxidative damage. *J. Nutr.* **2000**, *130*, 2115S–2119S.

101. Deprez, S.; Mila, I.; Huneau, J.F.; Tome, D.; Scalbert, A. Transport of proanthocyanidin dimer, trimer, and polymer across monolayers of human intestinal epithelial Caco-2 cells. *Antioxid. Redox Signal.* **2001**, *3*, 957–967.

102. Spencer, J.P.; Schroeter, H.; Shenoy, B.; Srai, S.K.; Debnam, E.S.; Rice-Evans, C. Epicatechin is the primary bioavailable form of the procyanidin dimers B2 and B5 after transfer across the small intestine. *Biochem. Biophys. Res. Commun.* **2001**, *285*, 588–593.

103. Ottaviani, J.I.; Momma, T.Y.; Heiss, C.; Kwik-Uribe, C.; Schroeter, H.; Keen, C.L. The stereochemical configuration of flavanols influences the level and metabolism of flavanols in humans and their biological activity *in vivo*. *Free Radic. Biol. Med.* **2011**, *50*, 237–244.

104. Ritter, C.; Zimmermann, B.F.; Galensa, R. Chiral separation of (+)/(-)-catechin from sulfated and glucuronidated metabolites in human plasma after cocoa consumption. *Anal. Bioanal. Chem.* **2010**, *397*, 723–730.

105. Rios, L.Y.; Bennett, R.N.; Lazarus, S.A.; Remesy, C.; Scalbert, A.; Williamson, G. Cocoa procyanidins are stable during gastric transit in humans. *Am. J. Clin. Nutr.* **2002**, *76*, 1106–1110.

106. Monagas, M.; Urpi-Sarda, M.; Sanchez-Patan, F.; Llorach, R.; Garrido, I.; Gomez-Cordoves, C.; Andres-Lacueva, C.; Bartolome, B. Insights into the metabolism and microbial biotransformation of dietary flavan-3-ols and the bioactivity of their metabolites. *Food Funct.* **2010**, *1*, 233–253.

107. Donovan, J.L.; Manach, C.; Faulks, R.M.; Kroon, P.A. Absorption and Metabolism of Plant Secondary Metabolites. In *Plant Secondary Metabolites: Occurrence, Structure and Role in the Human Diet*; Crozier, A., Clifford, M.N., Ashihara, H., Eds.; Blackwell Publishing: Oxford, UK, 2006; pp. 303–351.

108. Ottaviani, J.I.; Momma, T.Y.; Kuhnle, G.K.; Keen, C.L.; Schroeter, H. Structurally related (-)-epicatechin metabolites in humans: Assessment using *de novo* chemically synthesized authentic standards. *Free Radic. Biol. Med.* **2012**, *52*, 1403–1412.

109. Fogliano, V.; Corollaro, M.L.; Vitaglione, P.; Napolitano, A.; Ferracane, R.; Travaglia, F.; Arlorio, M.; Costabile, A.; Klinder, A.; Gibson, G. *In vitro* bioaccessibility and gut biotransformation of polyphenols present in the water-insoluble cocoa fraction. *Mol. Nutr. Food Res.* **2011**, *55*, S44–S55.

110. Stoupi, S.; Williamson, G.; Drynan, J.W.; Barron, D.; Clifford, M.N. A comparison of the *in vitro* biotransformation of (-)-epicatechin and procyanidin B2 by human faecal microbiota. *Mol. Nutr. Food Res.* **2010**, *54*, 747–759.

111. Rios, L.Y.; Gonthier, M.P.; Remesy, C.; Mila, I.; Lapierre, C.; Lazarus, S.A.; Williamson, G.; Scalbert, A. Chocolate intake increases urinary excretion of polyphenol-derived phenolic acids in healthy human subjects. *Am. J. Clin. Nutr.* **2003**, *77*, 912–918.

112. Meng, X.; Sang, S.; Zhu, N.; Lu, H.; Sheng, S.; Lee, M.J.; Ho, C.T.; Yang, C.S. Identification and characterization of methylated and ring-fission metabolites of tea catechins formed in humans, mice, and rats. *Chem. Res. Toxicol.* **2002**, *15*, 1042–1050.
113. Urpi-Sarda, M.; Llorach, R.; Khan, N.; Monagas, M.; Rotches-Ribalta, M.; Lamuela-Raventos, R.; Estruch, R.; Tinahones, F.J.; Andres-Lacueva, C. Effect of milk on the urinary excretion of microbial phenolic acids after cocoa powder consumption in humans. *J. Agric. Food Chem.* **2010**, *58*, 4706–4711.

114. Urpi-Sarda, M.; Monagas, M.; Khan, N.; Llorach, R.; Lamuela-Raventos, R.M.; Jauregui, O.; Estruch, R.; Izquierdo-Pulido, M.; Andres-Lacueva, C. Targeted metabolic profiling of phenolics in urine and plasma after regular consumption of cocoa by liquid chromatography-tandem mass spectrometry. *J. Chromatogr. A* **2009**, *1216*, 7258–7267.

115. Appeldoorn, M.M.; Vincken, J.P.; Aura, A.M.; Hollman, P.C.; Gruppen, H. Procyanidin dimers are metabolized by human microbiota with 2-(3,4-dihydroxyphenyl)acetic acid and 5-(3,4-dihydroxyphenyl)-gamma-valerolactone as the major metabolites. *J. Agric. Food Chem.* **2009**, *57*, 1084–1092.

116. Urpi-Sarda, M.; Monagas, M.; Khan, N.; Lamuela-Raventos, R.M.; Santos-Buelga, C.; Sacanella, E.; Castell, M.; Permanyer, J.; Andres-Lacueva, C. Epicatechin, procyanidins, and phenolic microbial metabolites after cocoa intake in humans and rats. *Anal. Bioanal. Chem.* **2009**, *394*, 1545–1556.

117. Depeint, F.; Gee, J.M.; Williamson, G.; Johnson, I.T. Evidence for consistent patterns between flavonoid structures and cellular activities. *Proc. Nutr. Soc.* **2002**, *61*, 97–103.

118. Scalbert, A.; Williamson, G. Dietary intake and bioavailability of polyphenols. *J. Nutr.* **2000**, *130*, 2073S–2085S.

119. Llorach, R.; Urpi-Sarda, M.; Tulipani, S.; Garcia-Aloy, M.; Monagas, M.; Andres-Lacueva, C. Metabolomic fingerprint in patients at high risk of cardiovascular disease by cocoa intervention. *Mol. Nutr. Food Res.* **2013**, *57*, 962–973.

120. Llorach-Asuncion, R.; Jauregui, O.; Urpi-Sarda, M.; Andres-Lacueva, C. Methodological aspects for metabolome visualization and characterization: A metabolomic evaluation of the 24 h evolution of human urine after cocoa powder consumption. *J. Pharm. Biomed. Anal.* **2010**, *51*, 373–381.

121. Llorach, R.; Urpi-Sarda, M.; Jauregui, O.; Monagas, M.; Andres-Lacueva, C. An LC-MS-based metabolomics approach for exploring urinary metabolome modifications after cocoa consumption. *J. Proteome Res.* **2009**, *8*, 5060–5068.

122. Ito, H.; Gonthier, M.P.; Manach, C.; Morand, C.; Mennen, L.; Remesy, C.; Scalbert, A. Polyphenol levels in human urine after intake of six different polyphenol-rich beverages. *Br. J. Nutr.* **2005**, *94*, 500–509.

123. Monagas, M.; Khan, N.; Andres-Lacueva, C.; Casas, R.; Urpi-Sarda, M.; Llorach, R.; Lamuela-Raventos, R.M.; Estruch, R. Effect of cocoa powder on the modulation of inflammatory biomarkers in patients at high risk of cardiovascular disease. *Am. J. Clin. Nutr.* **2009**, *90*, 1144–1150.

124. Khan, N.; Monagas, M.; Andres-Lacueva, C.; Casas, R.; Urpi-Sarda, M.; Lamuela-Raventos, R.M.; Estruch, R. Regular consumption of cocoa powder with milk increases HDL cholesterol and reduces oxidized LDL levels in subjects at high-risk of cardiovascular disease. *Nutr. Metab. Cardiovasc. Dis.* **2012**, *22*, 1046–1053.
125. Selma, M.V.; Espin, J.C.; Tomas-Barberan, F.A. Interaction between phenolics and gut microbiota: Role in human health. *J. Agric. Food Chem.* 2009, 57, 6485–6501.

126. Williamson, G.; Clifford, M.N. Colonic metabolites of berry polyphenols: The missing link to biological activity? *Br. J. Nutr.* 2010, 104, S48–S66.

127. Van Duynhoven, J.; Vaughan, E.E.; Jacobs, D.M.; Kemperman, R.A.; van Velzen, E.J.; Gross, G.; Roger, L.C.; Possemiers, S.; Smilde, A.K.; Dore, J.; *et al.* Metabolic fate of polyphenols in the human superorganism. *Proc. Natl. Acad. Sci. USA* 2011, 108, 4531–4538.

128. Dall’Asta, M.; Calani, L.; Tedeschi, M.; Jechiu, L.; Brighenti, F.; Del Rio, D. Identification of microbial metabolites derived from *in vitro* fecal fermentation of different polyphenolic food sources. *Nutrition* 2012, 28, 197–203.

129. Prakash, S.; Rodes, L.; Coussa-Charley, M.; Tomaro-Duchesneau, C. Gut microbiota: Next frontier in understanding human health and development of biotherapeutics. *Biol. Targets Ther.* 2011, 5, 71–86.

130. Clemente, J.C.; Ursell, L.K.; Parfrey, L.W.; Knight, R. The impact of the gut microbiota on human health: An integrative view. *Cell* 2012, 148, 1258–1270.

131. Flint, H.J.; Scott, K.P.; Louis, P.; Duncan, S.H. The role of the gut microbiota in nutrition and health. *Nat. Rev. Gastroenterol. Hepatol.* 2012, 9, 577–589.

132. Lozupone, C.A.; Stombaugh, J.I.; Gordon, J.I.; Jansson, J.K.; Knight, R. Diversity, stability and resilience of the human gut microbiota. *Nature* 2012, 489, 220–230.

133. Cardona, F.; Andres-Lacueva, C.; Tulipani, S.; Tinahones, F.J.; Queipo-Ortuno, M.I. Benefits of polyphenols on gut microbiota and implications in human health. *J. Nutr. Biochem.* 2013, 24, 1415–1422.

134. Bolca, S.; van de Wiele, T.; Possemiers, S. Gut metabotypes govern health effects of dietary polyphenols. *Curr. Opin. Biotechnol.* 2013, 24, 220–225.

135. Martin, F.P.; Montoliu, I.; Nagy, K.; Moco, S.; Collino, S.; Guy, P.; Redeuil, K.; Scherer, M.; Rezzi, S.; Kochhar, S. Specific dietary preferences are linked to differing gut microbial metabolic activity in response to dark chocolate intake. *J. Proteome Res.* 2012, 11, 6252–6263.

136. Serafini, M.; Bugianesi, R.; Maiani, G.; Valtuena, S.; de Santis, S.; Crozier, A. Plasma antioxidants from chocolate. *Nature 2003*, 424, 1013.

137. Roura, E.; Andres-Lacueva, C.; Estruch, R.; Lourdes Mata Bilbao, M.; Izquierdo-Pulido, M.; Lamuela-Raventos, R.M. The effects of milk as a food matrix for polyphenols on the excretion profile of cocoa (−)-epicatechin metabolites in healthy human subjects. *Br. J. Nutr.* 2008, 100, 846–851.

138. Roura, E.; Andres-Lacueva, C.; Estruch, R.; Mata-Bilbao, M.L.; Izquierdo-Pulido, M.; Waterhouse, A.L.; Lamuela-Raventos, R.M. Milk does not affect the bioavailability of cocoa powder flavonoid in healthy human. *Ann. Nutr. Metab.* 2007, 51, 493–498.

139. Schroeter, H.; Holt, R.R.; Orozco, T.J.; Schmitz, H.H.; Keen, C.L. Nutrition: Milk and absorption of dietary flavanols. *Nature 2003*, 426, 787–788.

140. Keogh, J.B.; McInerney, J.; Clifton, P.M. The effect of milk protein on the bioavailability of cocoa polyphenols. *J. Food Sci.* 2007, 72, S230–S233.
141. Schramm, D.D.; Karim, M.; Schrader, H.R.; Holt, R.R.; Kirkpatrick, N.J.; Polagruto, J.A.; Ensunsia, J.L.; Schmitz, H.H.; Keen, C.L. Food effects on the absorption and pharmacokinetics of cocoa flavanols. *Life Sci.* 2003, 73, 857–869.

142. Rodriguez-Mateos, A.; Oruna-Concha, M.J.; Kwik-Urrib, C.; Vidal, A.; Spencer, J.P. Influence of sugar type on the bioavailability of cocoa flavanols. *Br. J. Nutr.* 2012, 108, 2243–2250.

143. Ferruzzi, M.G.; Bordenave, N.; Hamaker, B.R. Does flavor impact function? Potential consequences of polyphenol-protein interactions in delivery and bioactivity of flavan-3-ols from foods. *Physiol. Behav.* 2012, 107, 591–597.

144. Neilson, A.P.; Ferruzzi, M.G. Influence of formulation and processing on absorption and metabolism of flavan-3-ols from tea and cocoa. *Annu. Rev. Food Sci. Technol.* 2011, 2, 125–151.

145. Neilson, A.P.; George, J.C.; Janle, E.M.; Mattes, R.D.; Rudolph, R.; Matsusheski, N.V.; Ferruzzi, M.G. Influence of chocolate matrix composition on cocoa flavan-3-ol bioaccessibility in vitro and bioavailability in humans. *J. Agric. Food Chem.* 2009, 57, 9418–9426.

146. Wan, Y.; Vinson, J.A.; Etherton, T.D.; Proch, J.; Lazarus, S.A.; Kris-Etherton, P.M. Effects of cocoa powder and dark chocolate on LDL oxidative susceptibility and prostaglandin concentrations in humans. *Am. J. Clin. Nutr.* 2001, 74, 596–602.

147. Rimbach, G.; Egert, S.; de Pascual-Teresa, S. Chocolate: (Un)healthy source of polyphenols? *Genes Nutr.* 2011, 6, 1–3.

148. Murphy, K.J.; Chronopoulos, A.K.; Singh, I.; Francis, M.A.; Moriarty, H.; Pike, M.J.; Turner, A.H.; Mann, N.J.; Sinclair, A.J. Dietary flavanols and procyanidin oligomers from cocoa (*Theobroma cacao*) inhibit platelet function. *Am. J. Clin. Nutr.* 2003, 77, 1466–1473.

149. Martin, F.P.; Rezzi, S.; Pere-Trepat, E.; Kamlage, B.; Collino, S.; Leibold, E.; Kastler, J.; Rein, D.; Fay, L.B.; Kochhar, S. Metabolic effects of dark chocolate consumption on energy, gut microbiota, and stress-related metabolism in free-living subjects. *J. Proteome Res.* 2009, 8, 5568–5579.

150. Rice-Evans, C. Flavonoid antioxidants. *Curr. Med. Chem.* 2001, 8, 797–807.

151. Kris-Etherton, P.M.; Keen, C.L. Evidence that the antioxidant flavonoids in tea and cocoa are beneficial for cardiovascular health. *Curr. Opin. Lipidol.* 2002, 13, 41–49.

152. McCullough, M.L.; Chevaux, K.; Jackson, L.; Preston, M.; Martinez, G.; Schmitz, H.H.; Coletti, C.; Campos, H.; Hollenberg, N.K. Hypertension, the Kuna, and the epidemiology of flavanols. *J. Cardiovasc. Pharmacol.* 2006, 47, S103–S109.

153. Mink, P.J.; Scrafford, C.G.; Barraj, L.M.; Harnack, L.; Hong, C.P.; Nettleton, J.A.; Jacobs, D.R., Jr. Flavonoid intake and cardiovascular disease mortality: A prospective study in postmenopausal women. *Am. J. Clin. Nutr.* 2007, 85, 895–909.

154. Baba, S.; Osakabe, N.; Kato, Y.; Natsume, M.; Yasuda, A.; Kido, T.; Fukuda, K.; Muto, Y.; Kondo, K. Continuous intake of polyphenolic compounds containing cocoa powder reduces LDL oxidative susceptibility and has beneficial effects on plasma HDL-cholesterol concentrations in humans. *Am. J. Clin. Nutr.* 2007, 85, 709–717.

155. Osakabe, N.; Baba, S.; Yasuda, A.; Iwamoto, T.; Kamiyama, M.; Takizawa, T.; Itakura, H.; Kondo, K. Daily cocoa intake reduces the susceptibility of low-density lipoprotein to oxidation as demonstrated in healthy human volunteers. *Free Radic. Res.* 2001, 34, 93–99.
156. Sarria, B.; Martinez-Lopez, S.; Sierra-Cinos, J.L.; Garcia-Diz, L.; Mateos, R.; Bravo, L. Regular consumption of a cocoa product improves the cardiometabolic profile in healthy and moderately hypercholesterolaemic adults. *Br. J. Nutr.* **2014**, *111*, 122–134.

157. Fisher, N.D.; Hollenberg, N.K. Aging and vascular responses to flavanol-rich cocoa. *J. Hypertens.* **2006**, *24*, 1575–1580.

158. Heiss, C.; Finis, D.; Kleinbongard, P.; Hoffmann, A.; Rassaf, T.; Kelm, M.; Sies, H. Sustained increase in flow-mediated dilation after daily intake of high-flavanol cocoa drink over 1 week. *J. Cardiovasc. Pharmacol.* **2007**, *49*, 74–80.

159. Heiss, C.; Kleinbongard, P.; Dejam, A.; Perre, S.; Schroeter, H.; Sies, H.; Kelm, M. Acute consumption of flavanol-rich cocoa and the reversal of endothelial dysfunction in smokers. *J. Am. Coll. Cardiol.* **2005**, *46*, 1276–1283.

160. Innes, A.J.; Kennedy, G.; McLaren, M.; Bancroft, A.J.; Belch, J.J. Dark chocolate inhibits platelet aggregation in healthy volunteers. *Platelets* **2003**, *14*, 325–327.

161. Balzer, J.; Rassaf, T.; Heiss, C.; Kleinbongard, P.; Lauer, T.; Merx, M.; Heussen, N.; Gross, H.B.; Keen, C.L.; Schroeter, H.; *et al.* Sustained benefits in vascular function through flavanol-containing cocoa in medicated diabetic patients a double-masked, randomized, controlled trial. *J. Am. Coll. Cardiol.* **2008**, *51*, 2141–2149.

162. Faridi, Z.; Njike, V.Y.; Dutta, S.; Ali, A.; Katz, D.L. Acute dark chocolate and cocoa ingestion and endothelial function: A randomized controlled crossover trial. *Am. J. Clin. Nutr.* **2008**, *88*, 58–63.

163. Lichtenstein, A.H.; Appel, L.J.; Brands, M.; Carnethon, M.; Daniels, S.; Franch, H.A.; Franklin, B.; Kris-Etherton, P.; Harris, W.S.; Howard, B.; *et al.* Summary of American heart association diet and lifestyle recommendations revision 2006. *Arterioscler. Thromb. Vasc. Biol.* **2006**, *26*, 2186–2191.

164. Baba, S.; Natsume, M.; Yasuda, A.; Nakamura, Y.; Tamura, T.; Osakabe, N.; Kanegae, M.; Kondo, K. Plasma LDL and HDL cholesterol and oxidized LDL concentrations are altered in normo- and hypercholesterolemic humans after intake of different levels of cocoa powder. *J. Nutr.* **2007**, *137*, 1436–1441.

165. Mursu, J.; Voutilainen, S.; Nurmi, T.; Rissanen, T.H.; Virtanen, J.K.; Kaikkonen, J.; Nyysonen, K.; Salonen, J.T. Dark chocolate consumption increases HDL cholesterol concentration and chocolate fatty acids may inhibit lipid peroxidation in healthy humans. *Free Radic. Biol. Med.* **2004**, *37*, 1351–1359.

166. Di Renzo, L.; Rizzo, M.; Sarlo, F.; Colica, C.; Iacopino, L.; Domino, E.; Sergi, D.; de Lorenzo, A. Effects of dark chocolate in a population of Normal Weight Obese women: A pilot study. *Eur. Rev. Med. Pharmacol. Sci.* **2013**, *17*, 2257–2266.

167. Steinberg, D. Low density lipoprotein oxidation and its pathobiological significance. *J. Biol. Chem.* **1997**, *272*, 20963–20966.

168. Witztum, J.L.; Steinberg, D. Role of oxidized low density lipoprotein in atherogenesis. *J. Clin. Investig.* **1991**, *88*, 1785–1792.

169. Fraley, A.E.; Tsimikas, S. Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. *Curr. Opin. Lipidol.* **2006**, *17*, 502–509.
170. Holvoet, P.; Lee, D.H.; Steffes, M.; Gross, M.; Jacobs, D.R., Jr. Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. *JAMA* 2008, 299, 2287–2293.

171. Ishigaki, Y.; Oka, Y.; Katagiri, H. Circulating oxidized LDL: A biomarker and a pathogenic factor. *Curr. Opin. Lipidol.* 2009, 20, 363–369.

172. Osakabe, N.; Yasuda, A.; Natsume, M.; Takizawa, T.; Terao, J.; Kondo, K. Catechins and their oligomers linked by C4→C8 bonds are major cacao polyphenols and protect low-density lipoprotein from oxidation in vitro. *Exp. Biol. Med.* 2002, 227, 51–56.

173. Richelle, M.; Tavazzi, I.; Offord, E. Comparison of the antioxidant activity of commonly consumed polyphenolic beverages (coffee, cocoa, and tea) prepared per cup serving. *J. Agric. Food Chem.* 2001, 49, 3438–3442.

174. Kurosawa, T.; Itoh, F.; Nozaki, A.; Nakano, Y.; Katsuda, S.; Osakabe, N.; Tsubone, H.; Kondo, K.; Itakura, H. Suppressive effects of cacao liquor polyphenols (CLP) on LDL oxidation and the development of atherosclerosis in Kurosawa and Kusanagi-hypercholesterolemic rabbits. *Atherosclerosis* 2005, 179, 237–246.

175. Kurosawa, T.; Itoh, F.; Nozaki, A.; Nakano, Y.; Katsuda, S.; Osakabe, N.; Tsubone, H.; Kondo, K.; Itakura, H. Suppressive effect of cocoa powder on atherosclerosis in Kurosawa and Kusanagi-hypercholesterolemic rabbits. *J. Atheroscler. Thromb.* 2005, 12, 20–28.

176. Mathur, S.; Devaraj, S.; Grundy, S.M.; Jialal, I. Cocoa products decrease low density lipoprotein oxidative susceptibility but do not affect biomarkers of inflammation in humans. *J. Nutr.* 2002, 132, 3663–3667.

177. Vita, J.A. Endothelial function and clinical outcome. *Heart* 2005, 91, 1278–1279.

178. Rein, D.; Paglieroni, T.G.; Wun, T.; Pearson, D.A.; Schmitz, H.H.; Gosselin, R.; Keen, C.L. Cocoa inhibits platelet activation and function. *Am. J. Clin. Nutr.* 2000, 72, 30–35.

179. Monahan, K.D. Effect of cocoa/chocolate ingestion on brachial artery flow-mediated dilation and its relevance to cardiovascular health and disease in humans. *Arch. Biochem. Biophys.* 2012, 527, 90–94.

180. Sies, H.; Schewe, T.; Heiss, C.; Kelm, M. Cocoa polyphenols and inflammatory mediators. *Am. J. Clin. Nutr.* 2005, 81, 304S–312S.

181. Fisher, N.D.; Hughes, M.; Gerhard-Herman, M.; Hollenberg, N.K. Flavanol-rich cocoa induces nitric-oxide-dependent vasodilation in healthy humans. *J. Hypertens.* 2003, 21, 2281–2286.

182. Heiss, C.; Dejam, A.; Kleinbongard, P.; Schewe, T.; Sies, H.; Kelm, M. Vascular effects of cocoa rich in flavan-3-ols. *JAMA* 2003, 290, 1030–1031.

183. Grassi, D.; Necozione, S.; Lippi, C.; Croce, G.; Valeri, L.; Pasqualetti, P.; Desideri, G.; Blumberg, J.B.; Ferri, C. Cocoa reduces blood pressure and insulin resistance and improves endothelium-dependent vasodilation in hypertensives. *Hypertension* 2005, 46, 398–405.

184. Fraga, C.G. Cocoa, diabetes, and hypertension: Should we eat more chocolate? *Am. J. Clin. Nutr.* 2005, 81, 541–542.

185. Flammer, A.J.; Hermann, F.; Sudano, I.; Spieker, L.; Hermann, M.; Cooper, K.A.; Serafini, M.; Luscher, T.F.; Ruschitzka, F.; Noll, G.; *et al.* Dark chocolate improves coronary vasomotion and reduces platelet reactivity. *Circulation* 2007, 116, 2376–2382.
186. Holt, R.R.; Actis-Goretta, L.; Momma, T.Y.; Keen, C.L. Dietary flavanols and platelet reactivity. *J. Cardiovasc. Pharmacol.* 2006, 47, S187–S196.
187. Ross, R. Atherosclerosis—An inflammatory disease. *N. Engl. J. Med.* 1999, 340, 115–126.
188. Pearson, T.A.; Mensah, G.A.; Alexander, R.W.; Anderson, J.L.; Cannon, R.O., 3rd; Criqui, M.; Fadl, Y.Y.; Fortmann, S.P.; Hong, Y.; Myers, G.L.; et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. *Circulation* 2003, 107, 499–511.
189. Tracy, R.P. Inflammation in cardiovascular disease: Cart, horse, or both? *Circulation* 1998, 97, 2000–2002.
190. Libby, P. Inflammation and cardiovascular disease mechanisms. *Am. J. Clin. Nutr.* 2006, 83, 456S–460S.
191. Di Giuseppe, R.; di Castelnuovo, A.; Centritto, F.; Zito, F.; de Curtis, A.; Costanzo, S.; Vohnout, B.; Sieri, S.; Krogh, V.; Donati, M.B.; et al. Regular consumption of dark chocolate is associated with low serum concentrations of C-reactive protein in a healthy Italian population. *J. Nutr.* 2008, 138, 1939–1945.
192. Abraham, J.; Campbell, C.Y.; Cheema, A.; Gluckman, T.J.; Blumenthal, R.S.; Danyi, P. C-reactive protein in cardiovascular risk assessment: A review of the evidence. *J. Cardiometab. Syndr.* 2007, 2, 119–123.
193. Kurlandsky, S.B.; Stote, K.S. Cardioprotective effects of chocolate and almond consumption in healthy women. *Nutr. Res.* 2006, 26, 509–516.
194. Tzounis, X.; Rodriguez-Mateos, A.; Vulevic, J.; Gibson, G.R.; Kwik-Uribe, C.; Spencer, J.P. Prebiotic evaluation of cocoa-derived flavanols in healthy humans by using a randomized, controlled, double-blind, crossover intervention study. *Am. J. Clin. Nutr.* 2011, 93, 62–72.
195. Stote, K.S.; Clevidence, B.A.; Novotny, J.A.; Henderson, T.; Radecki, S.V.; Baer, D.J. Effect of cocoa and green tea on biomarkers of glucose regulation, oxidative stress, inflammation and hemostasis in obese adults at risk for insulin resistance. *Eur. J. Clin. Nutr.* 2012, 66, 1153–1159.
196. Hamed, M.S.; Gambert, S.; Albido, K.P.; Bliden, O.; Singla, A.; Antonino, M.J.; Hamed, F.; Tantry, U.S.; Gurbel, P.A. Dark chocolate effect on platelet activity, C-reactive protein and lipid profile: A pilot study. *South. Med. J.* 2008, 101, 1203–1208.
197. Schisterman, E.F.; Mumford, S.L.; Sjaarda, L.A. Failure to consider the menstrual cycle phase may cause misinterpretation of clinical and research findings of cardiometabolic biomarkers in premenopausal women. *Epidemiol. Rev.* 2014, 36, 71–82.
198. Farouque, H.M.; Leung, M.; Hope, S.A.; Baldi, M.; Schechter, C.; Cameron, J.D.; Meredith, I.T. Acute and chronic effects of flavanol-rich cocoa on vascular function in subjects with coronary artery disease: A randomized double-blind placebo-controlled study. *Clin. Sci.* 2006, 111, 71–80.
199. Grassi, D.; Desideri, G.; Necozione, S.; Lippi, C.; Casale, R.; Properzi, G.; Blumberg, J.B.; Ferri, C. Blood pressure is reduced and insulin sensitivity increased in glucose-intolerant, hypertensive subjects after 15 days of consuming high-polyphenol dark chocolate. *J. Nutr.* 2008, 138, 1671–1676.
200. Wang-Polagruto, J.F.; Villablanca, A.C.; Polagruto, J.A.; Lee, L.; Holt, R.R.; Schrader, H.R.; Ensunsa, J.L.; Steinberg, F.M.; Schmitz, H.H.; Keen, C.L. Chronic consumption of flavanol-rich cocoa improves endothelial function and decreases vascular cell adhesion molecule in hypercholesterolemic postmenopausal women. *J. Cardiovasc. Pharmacol.* **2006**, *47*, S177–S186.

201. Muniyappa, R.; Hall, G.; Kolodziej, T.L.; Karne, R.J.; Crandon, S.K.; Quon, M.J. Cocoa consumption for 2 wk enhances insulin-mediated vasodilatation without improving blood pressure or insulin resistance in essential hypertension. *Am. J. Clin. Nutr.* **2008**, *88*, 1685–1696.

202. Nogueira Lde, P.; Knibel, M.P.; Torres, M.R.; Nogueira Neto, J.F.; Sanjuliand, A.F. Consumption of high-polyphenol dark chocolate improves endothelial function in individuals with stage 1 hypertension and excess body weight. *Int. J. Hypertens.* **2012**, 2012, 147321.

203. Vazquez-Agell, M.; Urpi-Sarda, M.; Sacanella, E.; Camino-Lopez, S.; Chiva-Blanch, G.; Llorente-Cortes, V.; Tobias, E.; Roura, E.; Andres-Lacueva, C.; Lamuela-Raventos, R.M.; *et al.* Cocoa consumption reduces NF-κB activation in peripheral blood mononuclear cells in humans. *Nutr. Metab. Cardiovasc. Dis.* **2013**, 23, 257–263.

204. Ridker, P.M.; Hennekens, C.H.; Roitman-Johnson, B.; Stampfer, M.J.; Allen, J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. *Lancet* **1998**, *351*, 88–92.

205. Blann, A.D.; Seigneur, M.; Steiner, M.; Miller, J.P.; McCollum, C.N. Circulating ICAM-1 and VCAM-1 in peripheral artery disease and hypercholesterolaemia: Relationship to the location of atherosclerotic disease, smoking, and in the prediction of adverse events. *Thromb. Haemost.* **1998**, 79, 1080–1085.

206. Von der Thüsen, J.H.; Kuiper, J.; van Berkel, T.J.C.; Biessen, E.A.L. Interleukins in atherosclerosis: Molecular pathways and therapeutic potential. *Pharmacol. Rev.* **2003**, 55, 133–166.

207. Thurberg, B.L.; Collins, T. The nuclear factor-κB/inhibitor of kappa B autoregulatory system and atherosclerosis. *Curr. Opin. Lipidol.* **1998**, 9, 387–396.

208. Funk, C.D. Leukotrienes as modifiers of preclinical atherosclerosis? *Sci. Transl. Med.* **2011**, 3, 66ps3.

209. Riccioni, G.; Back, M. Leukotrienes inflammatory mediators meet their match. *Sci. World J.* **2012**, 2012, 490968.

210. Gu, Y.; Yu, S.; Lambert, J.D. Dietary cocoa ameliorates obesity-related inflammation in high fat-fed mice. *Eur. J. Nutr.* **2014**, 53, 149–158.

211. Vinson, J.A.; Proch, J.; Bose, P.; Muchler, S.; Taffera, P.; Shuta, D.; Samman, N.; Agbor, G.A. Chocolate is a powerful ex vivo and in vivo antioxidant, an antiatherosclerotic agent in an animal model, and a significant contributor to antioxidants in the European and American Diets. *J. Agric. Food Chem.* **2006**, 54, 8071–8076.

212. Desch, S.; Schmidt, J.; Kobler, D.; Sonnabend, M.; Eitel, I.; Sareban, M.; Rahimi, K.; Schulter, G.; Thiele, H. Effect of cocoa products on blood pressure: Systematic review and meta-analysis. *Am. J. Hypertens.* **2010**, 23, 97–103.

213. Yakala, G.K.; Wielinga, P.Y.; Suarez, M.; Bunschoten, A.; van Golde, J.M.; Arola, L.; Keijer, J.; Kleemann, R.; Kooistra, T.; Heeringa, P. Effects of chocolate supplementation on metabolic and cardiovascular parameters in ApoE3L mice fed a high-cholesterol atherogenic diet. *Mol. Nutr. Food Res.* **2013**, 57, 2039–2048.
214. Ramos-Romero, S.; Pérez-Cano, F.J.; Pérez-Berezo, T.; Castellote, C.; Franch, A.; Catell, M. A seven-day high cocoa diet decreases oxidant and inflammatory properties of peritoneal macrophages in rats. *Proc. Nutr. Soc.* **2010**, *69*, E253.

215. Schewe, T.; Sadik, C.; Klotz, L.O.; Yoshimoto, T.; Kuhn, H.; Sies, H. Polyphenols of cocoa: Inhibition of mammalian 15-lipoxygenase. *Biol. Chem.* **2001**, *382*, 1687–1696.

216. Schewe, T.; Kuhn, H.; Sies, H. Flavonoids of cocoa inhibit recombinant human 5-lipoxygenase. *J. Nutr.* **2002**, *132*, 1825–1829.

217. Mao, T.; van de Water, J.; Keen, C.L.; Schmitz, H.H.; Gershwin, M.E. Cocoa procyanidins and human cytokine transcription and secretion. *J. Nutr.* **2000**, *130*, 2093S–2099S.

218. Mao, T.K.; Powell, J.; van de Water, J.; Keen, C.L.; Schmitz, H.H.; Hammerstone, J.F.; Gershwin, M.E. The effect of cocoa procyanidins on the transcription and secretion of interleukin 1 beta in peripheral blood mononuclear cells. *Life Sci.* **2000**, *66*, 1377–1386.

219. Mao, T.K.; Powell, J.; van de water, J.; Keen, C.L.; Schmitz, H.H.; Gershwin, M.E. Effect of cocoa procyanidins on the secretion of interleukin-4 in peripheral blood mononuclear cells. *J. Med. Food* **2000**, *3*, 107–114.

220. Mao, T.K.; van de Water, J.; Keen, C.L.; Schmitz, H.H.; Gershwin, M.E. Modulation of TNF-alpha secretion in peripheral blood mononuclear cells by cocoa flavanols and procyanidins. *Dev. Immunol.* **2002**, *9*, 135–141.

221. Mao, T.K.; van de Water, J.; Keen, C.L.; Schmitz, H.H.; Gershwin, M.E. Effect of cocoa flavanols and their related oligomers on the secretion of interleukin-5 in peripheral blood mononuclear cells. *J. Med. Food* **2002**, *5*, 17–22.

222. Ramiro, E.; Franch, A.; Castellote, C.; Perez-Cano, F.; Permanyer, J.; Izquierdo-Pulido, M.; Castell, M. Flavonoids from *Theobroma cacao* down-regulate inflammatory mediators. *J. Agric. Food Chem.* **2005**, *53*, 8506–8511.

223. Ramiro, E.; Franch, A.; Castellote, C.; Andres-Lacueva, C.; Izquierdo-Pulido, M.; Castell, M. Effect of *Theobroma cacao* flavonoids on immune activation of a lymphoid cell line. *Br. J. Nutr.* **2005**, *93*, 859–866.

224. Kenny, T.P.; Keen, C.L.; Schmitz, H.H.; Gershwin, M.E. Immune effects of cocoa procyanidin oligomers on peripheral blood mononuclear cells. *Exp. Biol. Med.* **2007**, *232*, 293–300.

225. Monagas, M.; Khan, N.; Andres-Lacueva, C.; Urpi-Sardà, M.; Vazquez-Agell, M.; Lamuela-Raventos, R.M.; Estruch, R. Dihydroxylated phenolic acids derived from microbial metabolism reduce lipopolysaccharide-stimulated cytokine secretion by human peripheral blood mononuclear cells. *Br. J. Nutr.* **2009**, *102*, 201–206.

226. Mackenzie, G.G.; Carrasquedo, F.; Delfino, J.M.; Keen, C.L.; Fraga, C.G.; Oteiza, P.I. Epicatechin, catechin, and dimeric procyanidins inhibit PMA-induced NF-κB activation at multiple steps in Jurkat T cells. *FASEB J.* **2004**, *18*, 167–169.

227. Kroon, P.A.; Clifford, M.N.; Crozier, A.; Day, A.J.; Donovan, J.L.; Manach, C.; Williamson, G. How should we assess the effects of exposure to dietary polyphenols in vitro? *Am. J. Clin. Nutr.* **2004**, *80*, 15–21.

228. Saliou, C.; Valacchi, G.; Rimbach, G. Assessing bioflavonoids as regulators of NF-κB activity and inflammatory gene expression in mammalian cells. *Methods Enzymol.* **2001**, *335*, 380–387.
229. Park, Y.C.; Rimbach, G.; Saliou, C.; Valacchi, G.; Packer, L. Activity of monomeric, dimeric, and trimeric flavonoids on NO production, TNF-alpha secretion, and NF-κB-dependent gene expression in RAW 264.7 macrophages. FEBS Lett. 2000, 465, 93–97.

230. Fraga, C.G.; Oteiza, P.I. Dietary flavonoids: Role of (−)-epicatechin and related procyanidins in cell signaling. Free Radic. Biol. Med. 2011, 51, 813–823.

231. Patel, K.R.; Andreadi, C.; Britton, R.G.; Horner-Glister, E.; Karmokar, A.; Sale, S.; Brown, V.A.; Brenner, D.E.; Singh, R.; Steward, W.P.; et al. Sulfate metabolites provide an intracellular pool for resveratrol generation and induce autophagy with senescence. Science Transl. Med. 2013, 5, 205ra133.

© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).